

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2016339404 B2**

(54) Title
Oxa spiro derivative, preparation method therefor, and applications thereof in medicines

(51) International Patent Classification(s)
C07D 409/14 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4436 (2006.01)

(21) Application No: **2016339404** (22) Date of Filing: **2016.09.30**

(87) WIPO No: **WO17/063509**

(30) Priority Data

(31) Number	(32) Date	(33) Country
201510665328.X	2015.10.15	CN
201511032876.5	2015.12.31	CN

(43) Publication Date: **2017.04.20**

(44) Accepted Journal Date: **2020.08.27**

(71) Applicant(s)
Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.

(72) Inventor(s)
Li, Xin; Feng, Binqiang; Chen, Yang; Liu, Tao; He, Feng; He, Mingxun; Tao, Weikang; Sun, Piaoyang

(74) Agent / Attorney
FB Rice Pty Ltd, Level 23 44 Market Street, Sydney, NSW, 2000, AU

(56) Related Art
CN 103702561 A

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局

(43) 国际公布日
2017 年 4 月 20 日 (20.04.2017)



(10) 国际公布号
WO 2017/063509 A1

- (51) 国际专利分类号:
C07D 409/14 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4436 (2006.01)
- (21) 国际申请号: PCT/CN2016/101064
- (22) 国际申请日: 2016 年 9 月 30 日 (30.09.2016)
- (25) 申请语言: 中文
- (26) 公布语言: 中文
- (30) 优先权:
201510665328.X 2015 年 10 月 15 日 (15.10.2015) CN
201511032876.5 2015 年 12 月 31 日 (31.12.2015) CN
- (71) 申请人: 江苏恒瑞医药股份有限公司 (JIANGSU HENGRUI MEDICINE CO., LTD.) [CN/CN]; 中国江苏省连云港市经济技术开发区昆仑山路 7 号, Jiangsu 222047 (CN)。上海恒瑞医药有限公司 (SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.) [CN/CN]; 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。
- (72) 发明人: 李心 (LI, Xin); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。冯斌强 (FENG, Bin-qiang); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。陈阳 (CHEN, Yang); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。刘涛 (LIU, Tao); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。贺峰 (HE, Feng); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。何明勋 (HE, Mingxun); 中国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。陶维康 (TAO, Weikang); 中

国上海市闵行区文井路 279 号, Shanghai 200245 (CN)。孙飘扬 (SUN, Piaoyang); 中国江苏省连云港市经济技术开发区昆仑山路 7 号, Jiangsu 200245 (CN)。


- (74) 代理人: 北京戈程知识产权代理有限公司 (GE CHENG & CO., LTD.); 中国北京市东城区东长安街 1 号东方广场东三办公楼 19 层程伟, Beijing 100738 (CN)。
- (81) 指定国 (除另有指明, 要求每一种可提供的国家保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW。
- (84) 指定国 (除另有指明, 要求每一种可提供的地区保护): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 欧洲 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)。

本国际公布:

— 包括国际检索报告 (条约第 21 条(3))。

(54) Title: OXA SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN MEDICINES

(54) 发明名称: 氧杂螺环类衍生物、其制备方法及其在医药上的应用



(57) Abstract: The present invention relates to an oxaspiro derivative, a preparation method therefor, and applications thereof in medicines. Particularly, the present invention relates to an oxaspiro derivative represented by formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative, applications thereof as an MOR receptor agonist, and applications in the preparation of drugs for treating and/or preventing pains and pains-related diseases. Substituent groups in the formula (I) are same as definitions in the specifications.

(57) 摘要: 本发明涉及氧杂螺环类衍生物、其制备方法及其在医药上的应用。特别地, 本发明涉及通式(I)所示的氧杂螺环类衍生物、其制备方法及其含有该衍生物的药物组合物, 以及其作为 MOR 受体激动剂的用途, 和其在制备治疗和/或预防疼痛和疼痛相关疾病的药物中的用途。其中通式(I)的各取代基同说明书中的定义相同。



WO 2017/063509 A1

OXA SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN MEDICINES

FIELD OF THE INVENTION

5

The present invention belongs to the field of medicine, and relates to an oxa spiro derivative, a preparation method therefor, and uses thereof in medicines. Particularly, the present invention relates to an oxa spiro derivative represented by formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative, use thereof as an MOR receptor agonist, and use thereof in the preparation of a medicament for treating and/or preventing pain and pain-related diseases.

BACKGROUND OF THE INVENTION

15 Opioid receptor is an important G protein-coupled receptor (GPCR), and is the target of combining endogenous opioid peptides and opioid drugs. The activated opioid receptors play a regulatory role on immune of the nervous system and endocrine system. Opioid drugs are the strongest and commonly used central analgesics. Endogenous opioid peptides are naturally occurring opioid-like active substances in mammals. Currently, the known endogenous opioid peptides can be roughly divided into 20 enkephalin, endorphin, dynorphin and nociceptin (Pharmacol Rev 2007; 59: 88-123). There are corresponding opioid receptors in the central nervous system, i.e., μ (MOR), δ (DOR), κ (KOR) receptors and the like. It is found that the strength of analgesic effect of endogenous opioid peptides mainly depends on the expression level of opioid receptors. 25 Opioid receptors are the targets of analgesic effect of opioid drugs and endogenous opioid peptides. Zadina et al found that the binding ability of MOR receptor to morphine peptide 1 is strongest (360 pM). It's 4000 times that of DOR receptor to morphine peptide 1, 15000 times that of KOR receptor to morphine peptide 1. The MOR receptor is the most important opioid receptor that mediates analgesic effect (Science, 2001, 293: 311-315; Biochem Biophys Res Commun 235:567-570; Life Sci 30 61:PL409-PL415).

The current studies suggest that GPCR mediates and regulates physiological functions mainly through two pathways: the G protein pathway and the β -arrestin pathway. The G protein signaling pathway can be activated by the binding of the 35 traditional GPCR agonist to the receptor, and includes the second messenger system such as calcium ion, adenylyl cyclase (AC), mitogen-activated protein kinases (MAPK) and on the like. While the β -arrestin pathway is mainly activated by a β -arrestin-biased ligand. The β -arrestin mediated GPCR response mainly includes three aspects: 1) β -arrestin as a negative regulator is reacted with the G protein-coupled receptor kinase (GRK), thereby causing receptor desensitization in GPCRs, and blocking the 40 transduction of G protein signaling; 2) β -arrestin as a scaffold protein recruits the

endocytic protein and induces the endocytosis of GPCR; 3) β -arrestin as an adapter protein forms a complex with GPCR downstream signal molecules, and activates the signal transduction molecules, such as MAPK, Src protein tyrosine kinase and Akt etc. in a G protein independent manner. The differences of ligand stimulation on G protein signaling and/or β -arrestin signaling ultimately determine the ligand-specific cellular biological effects of GPCR.


MOR is the target of opioid analgesic drugs such as endogenous enkephalin and morphine. Early studies have shown that endogenous enkephalin and opioid drug etorphine can agonize G protein and cause receptor endocytosis, but morphine can not cause receptor endocytosis at all. It is because the ability of morphine on agonizing MOR phosphorylation is too weak, and only trace β -arrestin is recruited on the membrane (Zhang et al., Proc Natl Acad Sci USA, 1998, 95 (12): 7157-7162). These ligands exert their physiological functions totally through the G protein signaling pathway rather than the β -arrestin pathway. The study found that after morphine is injected to β -arrestin2 knockout mice, the analgesic effect mediated by G protein signaling is stonger and the duration is longer (Bohn et al., Science, 1999). It is foreseeable that if the negative β -arrestin bias of such ligands is stronger, even they can escape the β -arrestin mediated receptor desensitization, thereby leading to longer G protein signaling durations and more potent analgesic effects.

Patent applications disclosing MOR agonists include International Patent Application Publication Nos. WO2014022733, WO2008009415, WO2009018169, WO2012129495, WO2001049650, WO2002020481, WO2010051476 and WO2013087589 and the like.

Long-term use of opioid drugs produces side effects such as tolerance, respiratory depression and constipation. And it has been demonstrated that these side effects are closely related to the function of β -arrestin. In order to reduce the side effects of opioid drugs, the drugs can be designed based on the MOR negative β -arrestin-biased ligand, thereby reducing the β -arrestin mediated side effects and enhancing the therapeutic effect. In a study of the oxo spiro derivatives of the present invention used as selective MOR drugs, Trevena Inc. has found that the activity is lower when the substituent is on the benzylic position of the aryl (J. Med. Chem. 2013, 56, 8019-8031), but after a series of studies, the present inventor has found the oxo spiro derivatives have high activity after the benzylic position is cyclized, Emax was also significantly improved, hERG was also improved significantly, and further studies found that the compound with a single configuration has a higher selectivity for the MOR.

SUMMARY OF THE INVENTION

The present invention is directed to a compound of formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof:



or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

5 ring A is selected from the group consisting of cycloalkyl and heterocyclyl;

R is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR³, -C(O)R³, -C(O)OR³,
10 -S(O)_mR³ and -NR⁴R⁵;

each R¹ is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR³, -C(O)R³, -C(O)OR³, -S(O)_mR³ and -NR⁴R⁵, wherein the alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are
15 each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

each R² is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR³, -C(O)R³, -C(O)OR³,
20 -S(O)_mR³ and -NR⁴R⁵, wherein the alkyl, alkoxy, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
25 heteroaryl;

or two R² are taken together to form a cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

30 R³ is selected from the group consisting of hydrogen, alkyl, deuterated alkyl, amino, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, halogen, hydroxy, amino, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;


35 R⁴ and R⁵ are each independently selected from the group consisting of hydrogen,

alkyl, alkoxy, hydroxyalkyl, hydroxy, amino, alkoxycarbonyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, halogen, hydroxy, amino, alkoxycarbonyl, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

p and q are each independently 0, 1, 2, 3 or 4; and

m is 0, 1 or 2.

In a preferred embodiment of the present invention, a compound of formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, is a compound of formula (I):



or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:

ring A, R, R¹, R², p and q are as defined in formula (I-A).

In a preferred embodiment of the present invention, in a compound of formula (I) or formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, ring A is selected from the group consisting of 5 to 6 membered heterocyclyl and 5 to 6 membered cycloalkyl.


In a preferred embodiment of the present invention, in a compound of formula (I) or formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, R is pyridyl.

In a preferred embodiment of the present invention, in a compound of formula (I) or formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, each R¹ is identical or different and each is independently selected from the group consisting of hydrogen and halogen.

In a preferred embodiment of the present invention, in a compound of formula (I) or formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, each R² is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, oxo, alkoxy, hydroxy, halogen and -OR³, wherein the alkyl and alkoxy are each optionally substituted by one or more groups selected from the group consisting of deuterium, alkyl, halogen, hydroxy, amino, alkoxycarbonyl, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R³ is selected from the

group consisting of hydrogen, alkyl and cycloalkyl, wherein the alkyl is optionally substituted by halogen or cycloalkyl.

In a preferred embodiment of the present invention, a compound of formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
 5 or a pharmaceutically acceptable salt thereof, is a compound of formula (II-A),



or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:


10 G is selected from the group consisting of a bond, CR^aR^b , $C=O$, NR^4 and oxygen;

R^a and R^b are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^3$, $-C(O)R^3$, $-C(O)OR^3$, $-S(O)_mR^3$ and $-NR^4R^5$, wherein the alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted
 15 by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, preferably hydroxy or $-OR^3$;

or R^a and R^b are taken together to form a cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted by one or more groups selected
 20 from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R^1 to R^5 , p, m and q are as defined in formula (I-A).

In a preferred embodiment of the present invention, a compound of formula (II-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
 25 or a pharmaceutically acceptable salt thereof, is a compound of formula (II-B):




or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

G is selected from the group consisting of a bond, CR^aR^b , $\text{C}=\text{O}$, NR^4 and oxygen;
and

R^1 , R^2 , R^4 , R^a , R^b , p and q are as defined in formula (II-A).

- 5 In a preferred embodiment of the present invention, a compound of formula (II-A),
or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
or a pharmaceutically acceptable salt thereof, is a compound of formula (II):




- or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
10 or a pharmaceutically acceptable salt thereof,
wherein:

G is selected from the group consisting of a bond, CR^aR^b , $\text{C}=\text{O}$, NR^4 and oxygen;
and

R^a , R^b , R^1 , R^2 , R^4 , p and q are as defined in formula (II-A).


- 15 In a preferred embodiment of the present invention, a compound of formula (II-A),
or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
or a pharmaceutically acceptable salt thereof, is a compound of formula (IV-A):



- or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
20 or a pharmaceutically acceptable salt thereof,
wherein:

R^1 , R^2 and p are as defined in formula (II-A).

- In a preferred embodiment of the present invention, a compound of formula (II),
or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof,
25 or a pharmaceutically acceptable salt thereof, is a compound of formula (IV):



(IV)






or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof.






wherein:






- 5 R^1 , R^2 and p are as defined in formula (II).






Typical compounds of formula (I-A) include, but are not limited to:






Example No.	Structure and Name
1	 <i>(S)</i> -1-ethyl- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydroquinolin-4-amine 1
2	 <i>(R)</i> -1-ethyl- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydroquinolin-4-amine 2
3	 <i>(1R,2R)</i> -1-((2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-2,3-dihydro-1 <i>H</i> -inden-2-ol 3
4	 <i>(1R,2R)</i> -2-methoxy- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1 <i>H</i> -inden-1-amine 4






5	
	<i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine
6	
	(<i>S</i>)- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine
7	
	(<i>R</i>)- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine
8	
	6-fluoro- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine
9	
	(<i>R</i>)- <i>N</i> -(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine

10	
	(S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine
11	
	(S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2H)-one
12	
	(1S,4S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-ol
13	
	(1R,4S)-4-((2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-ol
14	
	(1S,4S)-4-methoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine

15	 <p>15</p>
	(R)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1H-inden-1-amine
16	 <p>16</p>
	(S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1H-inden-1-amine
17	 <p>17</p>
	(1S,2S)-2-methoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1H-inden-1-amine
18	 <p>18</p>
	(1S,2S)-1-((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-2,3-dihydro-1H-inden-2-ol
19	 <p>19</p>
	(1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine


20	 <p>(1<i>S</i>,4<i>S</i>)-4-(cyclopropylmethoxy)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine</p>
21	 <p>(1<i>S</i>,4<i>S</i>)-4-(2-fluoroethoxy)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine</p>
22	 <p>(1<i>S</i>,4<i>S</i>)-4-(methoxymethyl)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine</p>
23	 <p>(1<i>S</i>,4<i>R</i>)-4-(methoxymethyl)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine</p>
24	 <p>(<i>S</i>)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-3',4'-dihydro-2'<i>H</i>-spiro[[1,3]dithiolane-2,1'-naphthalen]-4'-amine 24</p>

25	 <p>(1<i>S</i>,4<i>R</i>)-4-ethoxy-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 25</p>
26	 <p>(1<i>S</i>,4<i>S</i>)-4-(ethoxy-<i>d</i>₅)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 26</p>
27	 <p>(<i>S</i>)-4-ethyl-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2-dihydronaphthalen-1-amine 27</p>
28	 <p>(<i>S</i>)-4-methylene-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 28</p>
29	 <p>2-(((1<i>S</i>,4<i>S</i>)-4-((2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)acetonitrile 29</p>

30	 <p>(1<i>S</i>,4<i>R</i>)-4-methoxy-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 30</p>
31	 <p>2-((<i>S</i>,<i>E</i>)-4-((2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2<i>H</i>)-ylidene)acetonitrile 31</p>
32	 <p>2-((4<i>S</i>)-4-((2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile 32</p>
33	 <p>(<i>S</i>)-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-3,4-dihydro-2<i>H</i>-spiro[naphthalen-1,2'-[1,3]dioxolane]-4-amine 33</p>
34	 <p>(1<i>S</i>,4<i>S</i>)-4-propoxy-<i>N</i>-(2-((<i>R</i>)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 34</p>

or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is also directed to a process for preparing a compound of formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, comprising a step of:




reacting a compound of formula (VA) or hydrochloride thereof with a compound of formula (VIA) via a reductive amination to obtain the compound of formula (I-A);

wherein:

ring A, R, R¹, R², p and q are as defined in formula (I-A).

In another aspect, the present invention is also directed to a process for preparing the compound of formula (I-A), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, comprising a step of:




reacting a compound of formula (VB-A) with a compound of formula (VIB-A) or hydrochloride thereof via a reductive amination to obtain the compound of formula (I-A);

wherein:

ring A, R, R¹, R², p and q are as defined in formula (I-A).

In another aspect, the present invention is also directed to a process for preparing the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, comprising a step of:



reacting a compound of formula (VB) with a compound of formula (VIB) or hydrochloride thereof via a reductive amination to obtain the compound of formula (I);

wherein:

5 ring A, R, R¹, R², p and q are as defined in formula (I).

In another aspect, the present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound of each of the aforementioned formulas, or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients. The present invention is also directed to a process for the preparation of the aforementioned composition comprising a step of mixing a compound represented by each formula or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.

In another aspect, the present invention is also directed to a method of preventing and/or treating pain and pain related diseases in a subject by administering to the subject the compound of each formula, particularly formula (I), or pharmaceutical composition thereof.

20 The present invention is further directed to use of a compound of each formula, particularly formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for agonizing or antagonizing MOR receptor.

25 The present invention is further directed to use of a compound of each formula, particularly formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for preventing and/or treating a MOR agonist receptor mediated and related disease, wherein the disease is selected from the group consisting of pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urinary and reproductive diseases, cardiovascular diseases and respiratory diseases.

The present invention is further directed to use of a compound of each formula,

particularly formula (I), or a tautomer, mesomer, racemate, enantiomer,
diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition comprising the same, in the preparation of a
medicament for preventing or treating pain and pain-related diseases in mammals,
5 wherein the pain

can be postoperative pain, cancer-induced pain, neuropathic pain, traumatic pain and inflammation pain, etc., wherein the cancer can be selected from the group consisting of breast cancer, endometrial cancer, cervical cancer, skin cancer, prostate cancer, ovarian cancer, fallopian tube tumor, ovarian tumor, hemophilia and leukemia.

5 The present invention is also directed to a method for the prevention or treatment of a MOR agonist receptor mediated and related disease, comprising a step of administering to a patient in need thereof a therapeutically effective amount of a compound of each formula, particularly formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt
10 thereof. This method shows prominent efficacy and fewer side effects. Wherein the disease is selected from the group consisting of pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urinary and reproductive diseases, cardiovascular diseases and respiratory diseases; preferably pain.

In another aspect, the present invention is directed to a method for the prevention
15 or treatment of pain and pain-related diseases in mammals, comprising a step of administering to a patient in need thereof a therapeutically effective amount of a compound of each formula, particularly formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof. This method shows prominent efficacy and fewer side effects. Wherein the pain
20 can be postoperative pain, cancer-induced pain, neuropathic pain, traumatic pain and inflammation pain; wherein the cancer can be selected from the group consisting of breast cancer, endometrial cancer, cervical cancer, skin cancer, prostate cancer, ovarian cancer, fallopian tube tumor, ovarian tumor, hemophilia and leukemia.

The present invention is directed to a compound of each formula, particularly
25 formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same for use as a medicament for the treatment of immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urinary and reproductive disorders, drug and alcohol abuse, gastritis and diarrhea,
30 cardiovascular diseases, respiratory diseases and cough.

Pharmaceutical compositions containing the active ingredient can be in a form suitable for oral administration, for example, a tablet, troche, lozenge, aqueous or oily suspension, dispersible powder or granule, emulsion, hard or soft capsule, or syrup or elixir. Oral compositions can be prepared according to any method known in the art for
35 the preparation of pharmaceutical compositions. Such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, colorants and preservatives, in order to provide a pleasing and palatable pharmaceutical formulation. The tablet contains the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients suitable for the manufacture of a tablet.

40 Oral formulations can be provided as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium

phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with an a water-soluble carrier such as polyethyleneglycol or an oil medium such as peanut oil, liquid paraffin or olive oil.

5 An aqueous suspension contains the active ingredient in admixture with excipients suitable for the manufacture of an aqueous suspension.

The active ingredient in admixture with the dispersing or wetting agents, suspending agent or one or more preservatives can be prepared as a dispersible powder or granule suitable for the preparation of an aqueous suspension by adding water. Suitable dispersant or wetting agents and suspending agents are exemplified by those
10 already mentioned above. Additional excipients, such as sweetening, flavoring, and coloring agents, can also be added. These compositions can be preserved by adding an antioxidant such as ascorbic acid.

The present pharmaceutical composition can also be in the form of an oil-in-water emulsion.

15 The pharmaceutical composition of the present invention can be in the form of a sterile aqueous solution. Acceptable vehicles or solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution.

The pharmaceutical composition can be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration.

20 It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors including, but not limited to, the following factors: activity of a specific compound, age of the patient, weight of the patient, general health of the patient, behavior of the patient, diet of the patient, administration time, administration route, excretion rate, drug combination and the like. In addition, the best treatment, such as
25 treatment mode, daily dose of the compound of formula (I) or the type of pharmaceutically acceptable salt thereof can be verified by traditional therapeutic regimens.

DETAILED DESCRIPTION OF THE INVENTION

30

Unless otherwise stated, the terms used in the specification and claims have the meanings described below.

“Alkyl” refers to a saturated aliphatic hydrocarbon group including C₁ to C₂₀ straight chain and branched chain groups, preferably an alkyl having 1 to 12 carbon
35 atoms, and more preferably an alkyl having 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl,
40 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl,


2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 5 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and branched isomers thereof. More preferably, an alkyl group is a lower alkyl having 1 to 6 carbon atoms, and non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 10 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group can be substituted or unsubstituted. When substituted, the substituent group(s) can be substituted at any 15 available connection point. The substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, oxo, carboxy, and alkoxycarbonyl.

20 “Alkenyl” refers to an alkyl as defined above that has at least two carbon atoms and at least one carbon-carbon double bond, for example, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl and the like. The alkenyl group can be substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, 25 alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio and heterocyclic alkylthio.

“Cycloalkyl” refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more 30 preferably 3 to 6 carbon atoms, and most preferably 5 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like. Polycyclic cycloalkyl includes a cycloalkyl having a spiro ring, fused ring or bridged ring.

35 “Spiro cycloalkyl” refers to a 5 to 20 membered polycyclic group with rings connected through one common carbon atom (called a spiro atom), wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, preferably 6 to 14 membered spiro cycloalkyl, and more preferably 7 to 10 membered spiro cycloalkyl. According to the number of the spiro 40 atoms shared between the rings, spiro cycloalkyl can be divided into mono-spiro cycloalkyl, di-spiro cycloalkyl, or poly-spiro cycloalkyl, and preferably a mono-spiro


cycloalkyl or di-spiro cycloalkyl, and more preferably 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro cycloalkyl. Non-limiting examples of spiro cycloalkyls include:



5

“Fused cycloalkyl” refers to a 5 to 20 membered all-carbon polycyclic group, wherein each ring in the system shares an adjacent pair of carbon atoms with another ring, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, preferably 6 to 14 membered fused cycloalkyl, and more preferably 7 to 10 membered fused cycloalkyl. According to the number of membered rings, fused cycloalkyl can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic, or tricyclic fused cycloalkyl, and more preferably 5-membered/5-membered, or 5-membered/6-membered bicyclic fused cycloalkyl. Non-limiting examples of fused cycloalkyl include:


10



15

“Bridged cycloalkyl” refers to a 5 to 20 membered all-carbon polycyclic group, wherein every two rings in the system share two disconnected carbon atoms, wherein the rings can have one or more double bonds, but none of the rings has a completely conjugated pi-electron system, preferably 6 to 14 membered bridged cycloalkyl, and more preferably 7 to 10 membered bridged cycloalkyl. According to the number of membered rings, bridged cycloalkyl can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic bridged cycloalkyl, and more preferably bicyclic or tricyclic bridged cycloalkyl. Non-limiting examples of bridged cycloalkyls include:

20




25

The ring of cycloalkyl can be fused to the ring of aryl, heteroaryl or heterocyclyl, wherein the ring bound to the parent structure is cycloalkyl. Non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl and the like, preferably benzocyclopentyl, tetrahydronaphthyl. The cycloalkyl can be optionally substituted or
 5 unsubstituted. When substituted, the substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, oxo, carboxy and alkoxycarbonyl.


“Heterocyclyl” refers to a 3 to 20 membered saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group having one or more heteroatoms selected from the group consisting of N, O, and S(O)_m (wherein m is an integer of 0 to 2) as ring atoms, but excluding -O-O-, -O-S- and -S-S- in the ring, with the remaining ring atoms being carbon atoms. Preferably, heterocyclyl has 3 to 12 atoms wherein 1 to 4 atoms are
 15 heteroatoms, more preferably 3 to 8 atoms wherein 1 to 3 atoms are heteroatoms, and most preferably 5 to 6 atoms wherein 1 to 2 or 1 to 3 atoms are heteroatoms. Non-limiting examples of monocyclic heterocyclyl include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidyl, piperazinyl, morpholinyl,
 20 thiomorpholinyl, homopiperazinyl and the like, preferably tetrahydropyranyl, piperidyl or pyrrolidinyl. Polycyclic heterocyclyl includes a heterocyclyl having a spiro ring, fused ring or bridged ring.

“Spiro heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl with rings connected through one common atom (called a spiro atom), wherein the rings
 25 have one or more heteroatoms selected from the group consisting of N, O, and S(O)_m (wherein m is an integer of 0 to 2) as ring atoms, with the remaining ring atoms being carbon atoms, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, preferably 6 to 14 membered spiro heterocyclyl, and more preferably 7 to 10 membered spiro heterocyclyl.
 30 According to the number of the spiro atoms shared between the rings, spiro heterocyclyl can be divided into mono-spiro heterocyclyl, di-spiro heterocyclyl, or poly-spiro heterocyclyl, preferably mono-spiro heterocyclyl or di-spiro heterocyclyl, and more preferably 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered
 35 mono-spiro heterocyclyl. Non-limiting examples of spiro heterocyclyls include:




“Fused heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl group,


wherein each ring in the system shares an adjacent pair of atoms with another ring, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, and wherein the rings have one or more heteroatoms selected from the group consisting of N, O, and S(O)_m (wherein m is an integer of 0 to 2) as ring atoms, with the remaining ring atoms being carbon atoms; preferably 6 to 14 membered fused heterocyclyl, and more preferably 7 to 10 membered fused heterocyclyl. According to the number of membered rings, fused heterocyclyl can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyl, preferably bicyclic or tricyclic fused heterocyclyl, and more preferably 5-membered/5-membered, or 5-membered/6-membered bicyclic fused heterocyclyl. Non-limiting examples of fused heterocyclyl include:



“Bridged heterocyclyl” refers to a 5 to 14 membered polycyclic heterocyclyl group, wherein every two rings in the system share two disconnected atoms, wherein the rings can have one or more double bonds, but none of the rings has a completely conjugated pi-electron system, and the rings have one or more heteroatoms selected from the group consisting of N, O, and S (O)_m (wherein m is an integer of 0 to 2) as ring atoms, with the remaining ring atoms being carbon atoms, preferably 6 to 14 membered bridged heterocyclyl, and more preferably 7 to 10 membered bridged heterocyclyl. According to the number of membered rings, bridged heterocyclyl can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclyl, preferably bicyclic, tricyclic or tetracyclic bridged heterocyclyl, and more preferably bicyclic or tricyclic bridged heterocyclyl. Non-limiting examples of bridged heterocyclyls include:




The heterocyclyl ring can be fused to the ring of an aryl, heteroaryl or cycloalkyl, wherein the ring bound to the parent structure is heterocyclyl. Non-limiting examples include:




The heterocyclyl can be optionally substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, oxo, carboxy, and alkoxycarbonyl.

“Aryl” refers to a 6 to 14 membered all-carbon monocyclic ring or polycyclic fused ring (i.e. each ring in the system shares an adjacent pair of carbon atoms with another ring in the system) having a completely conjugated pi-electron system, preferably 6 to 10 membered aryl, and more preferably 5 to 6 membered aryl, for example, phenyl and naphthyl. The aryl ring can be fused to the ring of heteroaryl, heterocyclyl or cycloalkyl, wherein the ring bound to the parent structure is the aryl ring. Non-limiting examples include:



The aryl can be optionally substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, carboxy, alkoxycarbonyl.

“Heteroaryl” refers to a 5 to 14 membered heteroaromatic system having 1 to 4 heteroatoms selected from the group consisting of O, S and N as ring atoms, preferably 5 to 10 membered heteroaryl having 1 to 3 heteroatoms, and more preferably 5 or 6 membered heteroaryl having 1 to 2 heteroatoms, for example, imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazolyl, pyrazinyl and the like, preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl, and more preferably pyrazolyl. The heteroaryl ring can be fused to the ring of an aryl, heterocyclyl or cycloalkyl, wherein the ring bound to the parent structure is heteroaryl ring. Non-limiting examples include:



The heteroaryl can be optionally substituted or unsubstituted. When substituted, the

substituent group(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, carboxy and alkoxycarbonyl.

5 “Alkoxy” refers to an -O-(alkyl) or an -O-(unsubstituted cycloalkyl) group, wherein the alkyl is as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. The alkoxy can be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more groups independently selected from the group
10 consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, carboxy, and alkoxycarbonyl.

“Deuterated alkyl” refers to an alkyl substituted by deuterium atom(s), wherein the alkyl is as defined above.

15 “Hydroxyalkyl” refers to an alkyl substituted by hydroxy(s), wherein the alkyl is as defined above.

“Hydroxy” refers to an -OH group.

“Halogen” refers to fluorine, chlorine, bromine or iodine.

“Amino” refers to an -NH₂ group.

20 “Cyano” refers to a -CN group.

“Nitro” refers to an -NO₂ group.

“Carboxy” refers to a -C(O)OH group.

“Alkoxycarbonyl” refers to a -C(O)O(alkyl) or -C(O)O(cycloalkyl) group, wherein the alkyl and cycloalkyl are as defined above.

25 “Acyl halide” refers to a compound comprising a -C(O)-halogen group.

All of “X is selected from the group consisting of A, B, or C”, “X is selected from the group consisting of A, B and C”, “X is A, B or C”, “X is A, B and C” and the like, are the same meaning. It means that X can be any one or more of A, B, and C. “Optional” or “optionally” means that the event or circumstance described subsequently
30 can, but need not occur, and this description includes the situation in which the event or circumstance does or does not occur. For example, “the heterocyclic group optionally substituted by an alkyl” means that an alkyl group can be, but need not be, present, and this description includes the situation of the heterocyclic group being substituted by an alkyl and the heterocyclic group being not substituted by an alkyl.

35 “Substituted” refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently substituted by a corresponding number of substituents. It goes without saying that the substituents only exist in their possible chemical position. The person skilled in the art is able to determine whether the substitution is possible or impossible by experiments or theory without paying excessive
40 efforts. For example, the combination of amino or hydroxy having free hydrogen and carbon atoms having unsaturated bonds (such as olefinic) can be unstable.

A "pharmaceutical composition" refers to a mixture of one or more of the compounds according to the present invention or physiologically/pharmaceutically acceptable salts or prodrugs thereof and other chemical components, and other components such as physiologically/pharmaceutically acceptable carriers and excipients.

The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism, which is conducive to the absorption of the active ingredient, thus displaying biological activity.


A "pharmaceutically acceptable salt" refers to a salt of the compound of the present invention, which is safe and effective in mammals and has the desired biological activity.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.

SYNTHESIS METHOD OF THE COMPOUND OF THE PRESENT INVENTION

Disclosed herein is a process for preparing a compound of formula (I-A) of the present invention, or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, comprises the following step:




reacting a compound of formula (VA) or hydrochloride thereof with a compound of formula (VIA) via a reductive amination to obtain the compound of formula (I-A);

wherein:

ring A, R, R¹, R², p and q are as defined in formula (I-A).

The compound of formula (I-A) of the present invention can also be prepared as follows:

Scheme 2



reacting a compound of formula (VB-A) with formula (VIB-A) or hydrochloride thereof via a reductive amination to obtain the compound of formula (I-A);


wherein:

5 ring A, R, R^1 , R^2 , p and q are as defined in formula (I-A).

In another aspect, the present invention is also directed to a process for preparing the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, comprising a step of:

10

Scheme 1



reacting a compound of formula (VB) with a compound of formula (VIB) or hydrochloride thereof via a reductive amination to obtain the compound of formula (I);

wherein:

15 ring A, R, R^1 , R^2 , p and q are as defined in formula (I).

PREFERRED EMBODIMENTS

20 The present invention will be further described with reference to the following examples, but the examples should not be considered as limiting the scope of the invention.

Examples

25 The structures of the compounds are identified by nuclear magnetic resonance (NMR) and/or mass spectrometry (MS). NMR chemical shifts (δ) are given in 10^{-6} (ppm). NMR is determined by a Bruker AVANCE-400 machine. The solvents for determination are deuterated-dimethyl sulfoxide (DMSO- d_6), deuterated-chloroform

(CDCl₃) and deuterated-methanol (CD₃OD), and the internal standard is tetramethylsilane (TMS).

MS is determined by a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, type: Finnigan LCQ advantage MAX).

5 High performance liquid chromatography (HPLC) is determined on an Agilent 1200DAD high pressure liquid chromatography spectrometer (Sunfire C18 150×4.6 mm chromatographic column) and a Waters 2695-2996 high pressure liquid chromatography spectrometer (Gimini C18 150×4.6 mm chromatographic column).

10 The average kinase inhibition rates and IC₅₀ values are determined by a NovoStar ELISA (BMG Co., Germany).

Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate is used for thin-layer silica gel chromatography (TLC). The dimension of the silica gel plate used in TLC is 0.15 mm to 0.2 mm, and the dimension of the silica gel plate used in product purification is 0.4 mm to 0.5 mm.

15 Yantai Huanghai 200 to 300 mesh silica gel is used as a carrier for column chromatography.

The known raw materials of the present invention can be prepared by conventional synthesis methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc., or Dari chemical
20 Company, etc.

Unless otherwise stated, the reactions are carried out under nitrogen atmosphere or argon atmosphere.

The term “nitrogen atmosphere” or “argon atmosphere” means that a reaction flask is equipped with a 1 L nitrogen or argon balloon.

25 The term “hydrogen atmosphere” means that a reaction flask is equipped with a 1 L hydrogen balloon.

Pressurized hydrogenation reactions are carried out with a Parr 3916EKX hydrogenation instrument and a QL-500 hydrogen generator or HC2-SS hydrogenation instrument.

30 In hydrogenation reactions, the reaction system is generally vacuumed and filled with hydrogen, and the above operation is repeated three times.

CEM Discover-S 908860 type microwave reactor is used in microwave reaction.

Unless otherwise stated, the solution used in the reactions refers to an aqueous solution.

35 Unless otherwise stated, the reaction temperature in the reactions refers to room temperature, ranging from 20°C to 30°C.

The reaction process is monitored by thin layer chromatography (TLC), and the system of developing solvent includes: A: dichloromethane and methanol system, B: *n*-hexane and ethyl acetate system, C: dichloromethane and acetone system. The ratio of
40 the volume of the solvent can be adjusted according to the polarity of the compounds.


The elution system for purification of the compounds by column chromatography

and thin layer chromatography includes: A: dichloromethane and methanol system, B: *n*-hexane and ethyl acetate system, C: dichloromethane and acetone system. The ratio of the volume of the solvent can be adjusted according to the polarity of the compounds, and sometimes a little alkaline reagent such as triethylamine or acidic reagent such as acetic acid can be added.

Examples 1, 2

(*S*)-1-ethyl-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydroquinolin-4-amine **1**

(*R*)-1-ethyl-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydroquinolin-4-amine **2**



(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **1a** (294 mg, 1.135 mmol, prepared by a method disclosed in the patent application “WO2012129495”) and 1-ethyl-1,2,3,4-tetrahydroquinolin-4-amine **1b** (200 mg, 1.135 mmol, prepared by a method disclosed in the patent application “WO2014078454”) were dissolved in 15 mL of dichloromethane, and the mixture was stirred for 1 hour. Then, sodium triacetoxyborohydride (1.203 g, 5.675 mmol) was added, and the resulting mixture was stirred for 16 hours. 20 mL of water was added, and the reaction solution was extracted with dichloromethane (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by high performance liquid chromatography to obtain the title compound 1-ethyl-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydroquinolin-1-amine, which was then separated chirally (separation conditions: chiral preparative column Superchiral S-AD (Chiralway), 2 cm I.D. *25 cm, 5 μm; mobile phase: CO₂: methanol: diethanolamine = 75: 25: 0.05, flow rate: 50 g/min). The corresponding fractions were collected and concentrated under reduced pressure to give the title compounds **1** (98 mg, a brown oil) and **2** (95 mg, a yellow solid).

Example 1:

MS *m/z* (ESI): 420.3 [*M*+1];

Chiral HPLC analysis: retention time 4.028 min, chiral purity: 99.7% (chromatographic column: Superchiral S-AD (Chiralway), 0.46 cm I.D.*15 cm, 5 μm; mobile phase: CO₂: methanol: diethanolamine =75: 25: 0.05 (v/v/v))

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.54 (s, 1H), 7.72 (s, 1H), 7.45 (d, 1H), 7.20 (s, 1H),

6.95 (s, 1H), 6.78 (d, 1H), 6.52 (d, 1H), 6.37 (s, 1H), 3.60 (br, 2H), 3.18-3.43 (m, 3H), 2.99 (m, 1H), 2.33-2.45 (m, 3H), 1.77-1.99 (m, 3H), 1.19-1.60 (m, 12H), 1.00-1.06 (m, 4 H), 0.63 (m, 1H).

Example 2:


5 MS m/z (ESI): 420.3 [M+1];

Chiral HPLC analysis: retention time 3.725 mins, chiral purity: 99.8% (chromatographic column: Superchiral S-AD (Chiralway), 0.46 cm I.D.*15 cm, 5 μ m; mobile phase: CO₂: methanol: diethanolamine =75: 25: 0.05 (v/v/v))

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.53 (s, 1H), 7.72 (s, 1H), 7.46 (d, 1H), 7.20 (s, 1H),
10 6.97 (s, 1H), 6.85 (d, 1H), 6.54 (d, 1H), 6.40 (s, 1H), 3.61 (br, 2H), 3.17-3.25 (m, 3H), 3.00-3.01 (m, 1H), 2.33-2.46 (m, 3H), 1.78-1.97 (m, 3H), 1.24-1.65 (m, 12H), 1.01-1.06 (m, 4 H), 0.61 (m, 1H).

Example 3

15 (1*R*,2*R*)-1-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-2,3-dihydro-1*H*-inden-2-ol **3**




1a (50 mg, 0.193 mmol) and (1*R*,2*R*)-1-amino-2,3-dihydro-1*H*-inden-2-ol **3a** (31.6
20 mg, 0.212 mmol, prepared by a method disclosed in the patent application “WO2010148191”) were dissolved in 15 mL of dichloromethane, an appropriate amount of methanol was added to enhance solubility. The resulting mixture was stirred for 1 hour at room temperature, then sodium triacetoxyborohydride (200 mg, 0.965 mmol) was added. After stirring for 16 hours, the reaction solution was concentrated
25 under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **3** (50 mg, yield 66%) as a white solid.

MS m/z (ESI): 393.5 [M+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.51 (d, 1H), 7.73-7.66 (m, 1H), 7.37 (d, 1H),
30 7.28-7.20 (m, 3H), 7.19-7.12 (m, 2H), 4.75 (d, 1H), 4.61 (d, 1H), 3.82-3.71 (m, 4H), 3.41-3.31 (m, 2H), 2.30-2.89 (m, 2H), 2.41-2.25 (m, 2H), 1.96-1.90 (m, 2H), 1.85-1.61 (m, 4H), 1.61-1.25 (m, 6H).

Example 4

(1*R*,2*R*)-2-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dih



5 *tert*-butyl ((1*R*,2*R*)-2-methoxy-2,3-dihydro-1*H*-inden-1-yl)carbamate **4b**

tert-butyl ((1*R*,2*R*)-2-hydroxy-2,3-dihydro-1*H*-inden-1-yl)carbamate **4a** (350 mg, 1.34 mmol, prepared by a well known method disclosed in “*Angewandte Chemie-International Edition*, **2012**, 51(34), 8495-8499”) was dissolved in 15 mL of dichloromethane, then silver oxide (930 mg, 4.02 mmol), iodomethane (0.25 mL, 4.02 mmol) and a small amount of activated 4Å molecular sieves were added. The resulting mixture was stirred for 16 hours at room temperature, filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by thin layer chromatography with elution system B to obtain the title compound **4b** (200 mg, yield 57%) as a white solid.

15 MS *m/z* (ESI): 208.2 [*M*-56+1]

Step 2

(1*R*,2*R*)-2-methoxy-2,3-dihydro-1*H*-inden-1-amine 2,2,2-trifluoroacetate **4c**

4b (60 mg, 0.228 mmol) was dissolved in 5 mL of dichloromethane, then 0.5 mL of trifluoroacetic acid was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure to obtain the crude title compound **4c** (66 mg) as a yellow oil, which was used directly in the next step without further purification.

MS *m/z* (ESI): 164.2 [*M*+1]

Step 3

(1*R*,2*R*)-2-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1*H*-inden-1-amine **4**

1a (50 mg, 0.193 mmol) and the crude **4c** (66 mg, 0.228 mmol) were dissolved in 15 mL of dichloromethane. The resulting mixture was stirred for 30 minutes at room temperature, then sodium triacetoxyborohydride (200 mg, 0.965 mmol) was added. After stirring for 16 hours, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **4** (25 mg, yield 32%) as a light yellow oil.


MS *m/z* (ESI): 407.3 [*M*+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.55 (d, 1H), 7.71 (d, 1H), 7.58 (d, 1H), 7.40 (d, 1H),

7.28 (d, 1H), 7.25-7.10 (m, 3H), 4.39 (d, 1H), 4.26 (d, 1H), 3.82-3.70 (m, 5H), 3.30 (s, 3H), 2.88-2.30 (m, 2H), 2.40-2.26 (m, 2H), 1.96-1.91 (m, 2H), 1.85-1.62 (m, 4H), 1.61-1.24 (m, 6H).

Example 5

5 *N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine




(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (20 mg, 0.08 mmol, prepared by a method disclosed in the patent application “WO2012129495”) and chroman-4-amine **5b** (23 mg, 0.15 mmol, prepared by a method disclosed in “*Bioorganic & Medicinal Chemistry Letters*, 2011, 21(5), 1338-1341”) were dissolved in 10 mL of dichloromethane, and the mixture was stirred for 2 hours. Then, sodium triacetoxyborohydride (65 mg, 0.31 mmol) was added, and the resulting mixture was stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **5** (6 mg, yield 20%) as a yellow oil.

MS *m/z* (ESI): 393.5 [*M*+1]


¹H NMR (400 MHz, Methanol-*d*₄) δ 8.55 (s, 1H), 7.78 (t, 1H), 7.52 (d, 1H), 7.27 (d, 1H), 7.01-7.12 (m, 2H), 6.66-6.85 (m, 2H), 4.05-4.23 (m, 2H), 3.71-3.86 (m, 2H), 3.59-3.69 (m, 1H), 2.51-2.65 (m, 2H), 2.37-2.47 (m, 1H), 1.98-2.17 (m, 2H), 1.84-1.96 (m, 2H), 1.37-1.83 (m, 9H), 1.24-1.35 (m, 1H), 1.05-1.17 (m, 1H), 0.65-0.71 (m, 1H).

Example 6

(*S*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine



25





(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (80 mg, 0.31 mmol) and (*S*)-chroman-4-amine hydrochloride **6a** (86 mg, 0.46 mmol, prepared by a method disclosed in “*ACS Catalysis*, 3(4), 555-559; 2013”) were dissolved in 10 mL of a mixture of dichloromethane and methanol (V:V=5:1), and the mixture was stirred for 1 hour. Then, sodium triacetoxyborohydride (263 mg, 1.24 mmol) was added, and the resulting mixture was stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **6** (36 mg, yield 32.1%) as a white viscous solid.

MS *m/z* (ESI): 393.5 [M+1]

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.55 (d, 1H), 7.80-7.76 (m, 1H), 7.53 (d, 1H), 7.26-7.25 (m, 1H), 7.05-7.01 (m, 2H), 6.78-6.70 (m, 2H), 4.17-4.10 (m, 2H), 3.79-3.63 (m, 3H), 2.56-2.42 (m, 3H), 2.19-2.10 (m, 2H), 1.92-1.82 (m, 2H), 1.80-1.44 (m, 12H).

Example 7

(*R*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine



(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (80 mg, 0.31 mmol, prepared by a method disclosed in the patent application “WO2012129495”), (*R*)-chroman-4-amine hydrochloride **7a** (115 mg, 0.62 mmol, prepared by a method disclosed in “*European Journal of Organic Chemistry*, 2014(31), 7034-7038, 2014”) and sodium triacetoxyborohydride (197 mg, 0.93 mmol) were dissolved in 10 mL of a mixture of dichloromethane and methanol (V:V=5:1), and the mixture was stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **7** (30 mg, yield 24.8%) as a light yellow oil.


MS *m/z* (ESI): 393.5 [M+1]

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.63 (d, 1H), 7.93 (t, 1H), 7.64 (d, 1H), 7.39 (t, 1H), 7.29 (t, 1H), 7.19 (d, 1H), 6.81-6.97 (m, 2H), 4.25-4.35 (m, 1H), 4.14-4.24 (m, 1H), 3.79 (d, 2H), 2.47-2.65 (m, 3H), 2.13-2.32 (m, 3H), 1.87-2.03 (m, 2H), 1.72-1.85 (m, 2H), 1.40-1.71 (m, 5H), 1.25-1.35 (m, 2H), 1.06-1.15 (m, 1H), 0.66-0.75 (m, 1H).

5

Example 8

6-fluoro-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)chroman-4-amine




(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (30 mg, 0.12 mmol, prepared by a method disclosed in the patent application “WO2012129495”) and 6-fluorochroman-4-amine **8a** (39 mg, 0.23 mmol, prepared by a method disclosed in “*Bioorganic & Medicinal Chemistry Letters*, 2011, 21(5), 1338-1341”) were dissolved in 20 mL of dichloromethane, then sodium triacetoxyborohydride (74 mg, 0.35 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **8** (10 mg, yield 20.4%) as a light yellow solid.


MS *m/z* (ESI): 411.2 [M+1]

¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, 1H), 7.67-7.64 (m, 1H), 7.34-7.31 (m, 1H), 7.16-7.14 (m, 1H), 6.84-6.74 (m, 2H), 6.73-6.7 (m, 1H), 4.02-4.08 (m, 2H), 3.78-3.75 (m, 3H), 2.66-2.12 (m, 6H), 2.1-1.59 (m, 9H), 1.35-1.18 (m, 4H).

Example 9

(*R*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine






(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (35 mg, 0.14 mmol, prepared by a method disclosed in the patent application “WO2012129495”) and (*R*)-1,2,3,4-tetrahydronaphthalen-1-amine **9a** (40 mg, 0.27 mmol, prepared by a method disclosed in “*Angewandte Chemie-International Edition*, 45(28), 4641-4644, 2006”) were dissolved in 5 mL of dichloromethane. The resulting mixture was stirred for 1 hour, then sodium triacetoxyborohydride (144 mg, 0.68 mmol) was added. After stirring for 1 hour, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **9** (15 mg, yield 27.5%) as a yellow solid.

MS *m/z* (ESI): 391.2 [M+1]


¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, 1H), 7.65 (t, 1H), 7.32 (d, 1H), 7.16 (d, 1H), 7.11-7.07 (m, 3H), 7.05 (d, 1H), 3.77 (d, 2H), 3.60-3.57 (br, 1H), 2.73-2.70 (m, 3H), 2.45 (d, 1H), 2.34 (d, 1H), 2.15-2.08 (m, 1H), 2.05-2.02 (m, 1H), 1.91 (d, 1H), 1.75-1.70 (m, 12H), 1.50-1.44 (m, 3H).

Example 10

(*S*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine



20



(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (20 mg, 0.14 mmol, prepared by a method disclosed in the patent application “WO2012129495”) and (*S*)-1,2,3,4-tetrahydronaphthalen-1-amine **10a** (50 mg, 0.272 mmol, prepared by a method disclosed in “*Angewandte Chemie-International Edition*, 45(28), 4641-4644, 2006”) were dissolved in 20 mL of dichloromethane. The resulting mixture was stirred for 1 hour, then sodium triacetoxyborohydride (144 mg, 0.68 mmol) was added. After stirring for 1 hour, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to


obtain the title compound **10** (15 mg, yield 28.3%) as a yellow solid.

MS m/z (ESI): 391.2 [M+1]

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.77 (d, 1H), 8.28 (t, 1H), 7.92 (d, 1H), 7.71 (t, 1H), 7.33-7.19 (m, 4H), 4.38 (t, 1H), 3.80-3.74 (m, 2H), 3.23-3.11 (m, 1H), 3.08-2.98 (m, 1H), 2.87-2.82 (m, 2H), 2.56-2.48 (m, 3H), 2.26-2.04 (m, 5H), 1.85-1.81 (m, 3H), 1.56-1.32 (m, 5H), 1.34-1.31 (m, 1H), 0.82-0.79 (m, 1H).

Example 11

(*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2*H*)-one



Step 1

(*S*)-tert-butyl (1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **11a**

(*S*)-1,2,3,4-tetrahydronaphthalen-1-amine **10a** (3 g, 20.41 mmol, prepared by a method disclosed in "*Angewandte Chemie-International Edition*, 45(28), 4641-4644, 2006") was dissolved in 100 mL of dichloromethane, then triethylamine (5.7 mL, 40.82 mmol) and di-tert-butyl dicarbonate (4.9 g, 22.45 mmol) were added. After stirring for 12 hours, the reaction solution was washed with water (100 mL) and saturated sodium bicarbonate solution (100 mL) successively. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude compound **11a** (5.6 g) as a light yellow oil, which was used directly in the next step without further purification.

MS m/z (ESI): 248.3 [M+1]

Step 2

(*S*)-tert-butyl (4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **11b**

The crude (*S*)-tert-butyl (1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **11a** (5.6 g, 20.41 mmol) was dissolved in 90 mL of mixture of acetone and water (V/V=2:1), then magnesium sulfate (5.5 g, 45.66 mmol) was added and potassium permanganate (7.22 g, 45.66 mmol) was slowly added with stirring. The reaction system was stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography with elution system B to obtain the title compound **11b** (3.1 g, yield 52%) as a off-white solid.
MS m/z (ESI): 262.3 [M+1]

Step 3


(*S*)-4-amino-3,4-dihydronaphthalen-1(2*H*)-one **11c**
(*S*)-tert-butyl (4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **11b** (1 g, 3.83 mmol) was dissolved in 20 mL of dichloromethane, then 8 mL of 4*M* hydrogen chloride in 1,4-dioxane solution was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure, 10 mL of ethanol was added to the resulting residue, and 30% aqueous ammonia was added dropwise to adjust the pH to 8. The mixture was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **11c** (400 mg, yield 64.8%) as a green viscous material.
MS m/z (ESI): 162.3 [M+1]

Step 4

(*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2*H*)-one **11**
(*S*)-4-amino-3,4-dihydronaphthalen-1(2*H*)-one **11c** (200 mg, 1.24 mmol) and (*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (268 mg, 1.04 mmol, prepared by a method disclosed in the patent application “WO2012129495”) were dissolved in 20 mL of dichloromethane, and the mixture was stirred for 1 hour, then sodium triacetoxyborohydride (1.1 g, 5.18 mmol) was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **11** (136 mg, yield 32.4%) as a white solid.
MS m/z (ESI): 405.6 [M+1]
¹H NMR (400 MHz, Methanol-*d*₄) δ 8.73 (d, 1H), 8.15-8.09 (m, 2H), 7.83 (d, 1H), 7.81-7.69 (m, 3H), 7.47 (d, 1H), 4.45 (t, 1H), 3.77-3.74 (m, 2H), 3.03-2.98 (m, 1H), 2.75-2.68 (m, 3H), 2.51-2.44 (m, 5H), 2.05-2.01 (m, 2H), 1.57-1.48 (m, 7H), 1.20-1.05 (m, 1H), 0.80-0.77 (m, 1H).

Example 12 and Example 13

(1*S*,4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-ol **12**
(1*R*,4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-ol **13**



(*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2*H*)-one **11** (50 mg, 0.12 mmol) was dissolved in 10 mL of dichloromethane, 0.29 mL of 1*M* diisobutyl aluminium hydroxide solution was added dropwise at -78°C , and the mixture was stirred for 2 hour at -78°C . 5 mL of methanol was added to quench the reaction. The reaction solution was warmed up to room temperature, and concentrated under reduced pressure. The resulting residue was purified by thin layer chromatography with elution system A to obtain the title compounds **12** (18 mg, yield 35.3%) as a off-white viscous solid and **13** (20 mg, yield 39.2%) as a off-white viscous solid.

12: MS *m/z* (ESI): 407.6 [*M*+1].


^1H NMR(400MHz, CDCl_3) δ 8.51(d, 1H), 7.50(t, 1H), 7.36(d, 1H), 7.33-7.30(m, 3H), 7.21-7.18 (m, 2H), 4.83(t, 1H), 4.25(t, 1H), 3.81-3.75(m, 2H), 2.85-2.83(m, 1H), 2.36-2.30(m, 5H), 1.98-1.80(m, 2H) , 1.78-1.60(m, 9H), 1.48-1.25(m, 5H).


13: MS *m/z* (ESI): 407.6 [*M*+1].

^1H NMR(400MHz, CDCl_3) δ 8.51(d, 1H), 7.50(t, 1H), 7.36(d, 1H), 7.33-7.30(m, 3H), 7.21-7.18 (m, 2H), 4.83(t, 1H), 4.25(t, 1H), 3.81-3.75(m, 2H), 2.85-2.83(m, 1H), 2.36-2.30(m, 5H), 1.98-1.80(m, 2H) , 1.78-1.60(m, 9H), 1.48-1.25(m, 5H).

Example 14

(1*S*,4*S*)-4-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine





Step 1

tert-butyl ((1*S*,4*S*)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **14a**
 (S)-*tert*-butyl (4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **11b** (100 mg, 0.883 mmol) was dissolved in 5 mL of toluene, the reaction was cooled to 0°C, added with (R)-2-methyl-CBS-oxazaborolidine (0.1 ml, 0.076 mmol), and stirred for 5 minutes. Then, borane methylsulfide (0.88 ml, 0.76 mmol) was added, and the reaction was stirred for 2 hours. The reaction was quenched by adding 50 ml of saturated sodium chloride solution, and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×3), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **14a** (60 mg, yield 60%) as a white solid.
 MS *m/z* (ESI): 208.3 [M-55]

Step 2

tert-butyl ((1*S*,4*S*)-4-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **14b**
 The crude compound **14a** (30 mg, 0.11 mmol) was dissolved in 4 mL of dichloromethane, then silver oxide (76 mg, 0.33 mmol) and methyl iodide (62 mg, 0.44 mmol) were added. After stirring for 48 hours, the reaction solution was filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound **14b** (30 mg) as a yellow oil, which was used directly in the next step without further purification.
 MS *m/z* (ESI): 278.4 [M+1].

Step 3

(1*S*,4*S*)-4-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride **14c**
 The crude compound **14b** (30 mg, 0.11 mmol) was dissolved in 0.5 mL of dichloromethane, then 1 mL of a solution of 4*M* hydrogen chloride in 1,4-dioxane was added. The reaction was stirred for 2.5 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound **14c** (24 mg) as a white solid, which was used directly in next step without further purification.

MS m/z (ESI): 178.4 [M+1].

Step 4

(1*S*,4*S*)-4-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **14**


5 Compound **5a** (29 mg, 0.11 mmol), the crude compound **14c** (24 mg, 0.11 mmol) and sodium sulfate were dissolved in 4 mL of methanol, and the mixture was stirred for 12 hours. Then, sodium borohydride (8 mg, 0.22 mmol) was added, and the mixture was stirred for 15 minutes. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system
10 A to obtain the title compound **14** (4 mg, yield 8.7%) as a white solid.

MS m/z (ESI): 407.6 [M+1]

¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, 1H), 7.66 (t, 1H), 7.33 (d, 1H), 7.15 (d, 1H), 7.08-7.06 (m, 3H), 7.04 (d, 1H), 3.76 (d, 2H), 3.61-3.58 (br, 1H), 3.41 (s, 3H), 2.74-2.72 (m, 3H), 2.46 (d, 1H), 2.32 (d, 1H), 2.13-2.08 (m, 1H), 2.03-2.00 (m, 1H), 1.90 (d, 1H),
15 1.75-1.72 (m, 11H), 1.51-1.46 (m, 3H).

Example 15

(*R*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1*H*-inden-1-amine



(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (20 mg, 0.08 mmol) and (*R*)-2,3-dihydro-1*H*-inden-1-amine hydrochloride **15a** (27 mg, 0.16 mmol, prepared by a method disclosed in “*Synthesis*, (14), 2283-2287, 2008”) were dissolved
25 in 10 mL of dichloromethane, and the mixture was stirred for 2 hours, then sodium triacetoxyborohydride (51 mg, 0.24 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **15** (5 mg, yield 16.7%) as a yellow oil.


30 MS m/z (ESI): 377.5 [M+1]

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.62 (d, 1H), 7.91 (t, 1H), 7.60 (d, 1H), 7.37 (s, 4H), 7.35 (d, 1H), 4.64-4.70 (m, 1H), 3.76 (d, 2H), 2.91-3.15 (m, 2H), 2.41-2.60 (m,

4H), 1.85-2.11 (m, 4H), 1.70-1.81 (m, 2H), 1.41-1.69 (m, 5H), 1.31-1.39 (m, 1H), 1.10-1.20 (m, 1H), 0.71-0.80 (m, 1H).

Example 16

5 (S)-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1H-inden-1-amine




10 (R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (20 mg, 0.08 mmol) and (S)-2,3-dihydro-1H-inden-1-amine hydrochloride **16a** (26 mg, 0.15 mmol, prepared by a method disclosed in “*Tetrahedron Asymmetry*, 14(22), 3479-3485; 2003”) were dissolved in 10 mL of dichloromethane, and the mixture was stirred for 2 hours, then sodium triacetoxyborohydride (49 mg, 0.23 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **16** (5 mg, yield 17%) as a yellow oil.


MS m/z (ESI): 377.5 [M+1]

¹H NMR (400 MHz, Methanol-*d*₄) δ 8.63 (d, 1H), 7.90 (t, 1H), 7.60 (d, 1H), 7.38 (s, 4H), 7.35 (d, 1H), 4.65-4.70 (m, 1H), 3.76 (d, 2H), 2.90-3.16 (m, 2H), 2.40-2.60 (m, 4H), 1.85-2.10 (m, 4H), 1.70-1.80 (m, 2H), 1.40-1.69 (m, 5H), 1.30-1.39 (m, 1H), 1.10-1.20 (m, 1H), 0.70-0.80 (m, 1H).

Example 17

25 (1S,2S)-2-methoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1H-inden-1-amine





Step 1

(1*S*,2*S*)-2-methoxy-2,3-dihydro-1*H*-inden-1-amine trifluoroacetate **17b**

tert-butyl ((1*S*,2*S*)-2-methoxy-2,3-dihydro-1*H*-inden-1-yl)carbamate **17a** (110 mg, 0.42 mmol, prepared by a method disclosed in the patent application “WO2008080015”) was dissolved in 5 mL of dichloromethane, then 1 mL of trifluoroacetic acid was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography with elution system A to obtain the crude title compound **17b** (70 mg, yield 60.3%) as a yellow oil.

MS *m/z* (ESI): 164.1 [*M*+1].

Step 2

(1*S*,2*S*)-2-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-2,3-dihydro-1*H*-inden-1-amine **17**


(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (25 mg, 0.96 mmol) and (1*S*,2*S*)-2-methoxy-2,3-dihydro-1*H*-inden-1-amine trifluoroacetate **17b** (54 mg, 0.19 mmol) were dissolved in 10 mL of dichloromethane, then sodium triacetoxyborohydride (61 mg, 0.29 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **17** (10 mg, yield 25.5%) as a yellow oil.


MS *m/z* (ESI): 407.6 [*M*+1]

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, 1H), 7.71 (t, 1H), 7.57 (d, 1H), 7.40 (d, 1H), 7.29 (d, 1H), 7.16-7.24 (m, 3H), 3.77 (d, 3H), 3.31 (s, 3H), 2.87-3.05 (m, 2H), 2.24-2.50 (m, 4H), 2.14-2.24 (m, 1H), 1.61-1.84 (m, 4H), 1.35-1.51 (m, 5H), 1.24-1.35 (m, 2H), 1.11-1.20 (m, 1H), 0.65-0.75 (m, 1H).

Example 18

(1*S*,2*S*)-1-((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-2,3-dihydro-1*H*-inden-2-ol





Step 1

2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **18b**

2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile **18a** (500 mg, 1.95 mmol, prepared by a method disclosed in the patent application “WO2012129495”) was dissolved in 20 mL of toluene, 4.2 mL of 1 M diisobutylaluminum hydride solution was slowly added dropwise at -78°C, and the reaction was stirred for 1.5 hours. Then, 18 mL of 2 M hydrochloric acid was added, and the mixture was stirred for 30 minutes. 5 M sodium hydroxide solution was added dropwise until the pH of the reaction solution was 9 to 10. The mixture was warmed up to room temperature and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×3), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography with elution system A to obtain the title compound **18b** (270 mg, yield 53.4%) as a yellow oil.

MS m/z (ESI): 260.5 [M+1].

Step 2


(1S,2S)-1-((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-2,3-dihydro-1H-inden-2-ol **18**

Compound **18b** (20 mg, 0.08 mmol) and (1S,2S)-1-amino-2,3-dihydro-1H-inden-2-ol **18c** (23 mg, 0.15 mmol, prepared by a method disclosed in “*Advanced Synthesis & Catalysis*, 350(14+15), 2250-2260; 2008”) were dissolved in 15 mL of a mixture of dichloromethane and methanol (V:V = 5:1), the mixture was stirred for 2 hours, then sodium triacetoxyborohydride (49 mg, 0.23 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **18** (10 mg, yield 33%) as a yellow oil.

MS m/z (ESI): 393.5 [M+1]

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, 1H), 7.70 (t, 1H), 7.37 (d, 1H), 7.20-7.26 (m, 3H), 7.11-7.19 (m, 2H), 3.76 (d, 3H), 3.36 (d, 1H), 2.88-3.05 (m, 2H), 2.25-2.50 (m, 4H), 2.15-2.24 (m, 1H), 1.60-1.84 (m, 4H), 1.36-1.51 (m, 5H), 1.25-1.35 (m, 2H), 1.10-1.20 (m, 1H), 0.65-0.75 (m, 1H).

(1*S*,4*S*)-4-ethoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine



tert-butyl ((1*S*,4*S*)-4-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **19a**

The crude compound *tert*-butyl ((1*S*)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **14a** (850 mg, 3.23 mmol), silver oxide (76 mg, 0.33 mmol) and iodoethane (1.3 mL, 16.15 mmol) were dissolved in 30 mL of dichloromethane, and the mixture was stirred for 48 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude compound **19a** (800 mg) as a yellow oil, which was used directly in the next step without further purification.

MS *m/z* (ESI): 236.1 [*M*-55].

Step 2

(1*S*,4*S*)-4-ethoxy-1,2,3,4-tetrahydronaphthalen-1-amine **19b**

The crude compound **19a** (698 mg, 2.4 mmol) was dissolved in 4 mL of dichloromethane, then 8 mL of a solution of 4 *M* hydrogen chloride in 1,4-dioxane was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure, triturated with ethyl acetate (30 mL) and filtered. The filter cake was dissolved in a 20 mL of a mixture of dichloromethane and methanol (V:V=5:1). Saturated sodium bicarbonate solution was added to adjust the pH of the reaction solution to 7 to 8. The reaction solution was concentrated under reduced pressure, washed with a mixture of dichloromethane and methanol (V:V=5:1) (30 mL×2) and filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound **19b** (310 mg) as a yellow liquid, which was used directly in next step without further purification.

MS *m/z* (ESI): 191.1 [*M*+1].

Step 3

(1*S*,4*S*)-4-ethoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **19**

(*R*)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde **5a** (500 mg, 1.85 mmol) and the crude compound **19b** (310 mg, 1.85 mmol) were dissolved in 30 mL of dichloromethane, and the mixture was stirred for 40 minutes, then sodium triacetoxyborohydride (980 mg, 4.63 mmol) was added. After stirring for 2 hours, the


reaction solution was washed successively with saturated sodium bicarbonate solution (30 mL×3) and saturated sodium chloride solution (30 mL×3). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **19** (280 mg, yield 35%) as a yellow viscous solid.

MS *m/z* (ESI): 435.3 [M+1]

¹H NMR (400 MHz, CDCl₃) δ 9.74 (d, 1H), 9.58 (d, 1H), 8.94 (d, 1H), 8.37 (d, 1H), 7.94 (d, 1H), 7.67 (d, 1H), 7.52 (d, 1H), 7.47 (t, 1H), 4.46-4.49 (m, 1H), 4.30-4.33 (m, 1H), 3.84-3.87 (m, 1H), 3.66-3.70 (m, 2H), 3.53-3.56 (m, 2H), 2.82-2.85 (d, 2H), 2.67 (s, 2H), 2.39-2.41 (m, 4H), 2.30-2.33 (m, 4H), 1.85 (s, 2H), 1.48-1.52 (m, 6H), 1.27 (m, 3H).

Example 20

(1*S*,4*S*)-4-(cyclopropylmethoxy)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine



Step 1

tert-butyl ((*S*)-4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **20a**

Compound **11** (220 mg, 0.54 mmol), di-*tert*-butyl dicarbonate (173 mg, 0.82 mmol) and triethylamine (0.15 mL, 1.08 mmol) were dissolved in 20 mL of dichloromethane. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with

elution system A to obtain the title compound **20a** (100 mg, yield 37%) as a light yellow viscous solid.

MS m/z (ESI): 505.3 [M+1].

Step 2

5 *tert*-butyl ((1*S*,4*S*)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **20b**

Compound **20a** (100 mg, 0.2 mmol) and 1*M* (*R*)-2-methyl-CBS-oxazaborolidine (0.04 mL, 0.4 mmol) were dissolved in 10 mL of toluene, the reaction was cooled to 0°C, then 2 *M* borane methylsulfide (0.02 mL, 0.4 mmol) was added. The reaction was
10 warmed up to room temperature and stirred for 3 hours. The reaction was quenched by adding 10 ml of saturated sodium chloride solution and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin
15 layer chromatography with elution system A to obtain the title compound **20b** (10 mg, yield 10%) as a white solid.

MS m/z (ESI): 507.3 [M+1].

Step 3

20 *tert*-butyl ((1*S*,4*S*)-4-(cyclopropylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **20c**

Compound **20b** (10 mg, 0.02 mmol) was dissolved in 5 ml of *N,N*-dimethylformamide, then sodium hydride (2.2 mg, 0.06 mmol) was added. The mixture was stirred for 30 minutes, then cyclopropylmethyl bromide (6.7 mg, 0.05 mmol) was added. After stirring for 3 hours, the reaction was quenched by adding 20 ml
25 of water and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound **20c** (5 mg) as a white solid, which was used directly in next step without further purification.

30 MS m/z (ESI): 561.0 [M+1].

Step 4

(1*S*,4*S*)-4-(cyclopropylmethoxy)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **20d**

The crude compound **20c** (5 mg, 0.0089 mmol) was dissolved in 5 mL of
35 dichloromethane, then 0.1 mL of a solution of 4 *M* hydrochloric acid in 1,4-dioxane was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **20d** (3 mg, yield 73.2%) as a white solid.

MS m/z (ESI): 461.3 [M+1]


40 ¹H NMR (400 MHz, CD₃OD) δ 8.59 (d, 1H), 7.84-7.81 (m, 1H), 7.55 (d, 1H), 7.53 (d, 1H), 7.47-7.40 (m, 1H), 7.39-7.29 (m, 2H), 7.25 (d, 1H), 4.48-4.46 (m, 1H), 4.28-4.25

(m, 1H), 3.77-3.75 (m, 2H), 3.45-3.43 (m, 2H), 3.35-3.30 (m, 2H), 2.93-2.92 (m, 1H), 2.53-2.50 (m, 2H), 2.49-2.48 (m, 1H), 2.25-2.13 (m, 2H), 1.95-1.31 (m, 11H), 1.10-1.08 (m, 2H), 0.76-0.73 (m, 1H), 0.55-0.53 (m, 2H), 0.25-0.23 (m, 2H).

5

Example 21

(1*S*,4*S*)-4-(2-fluoroethoxy)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine



10

Step 1

tert-butyl ((1*S*,4*S*)-4-(2-fluoroethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **21a**

20b (45 mg, 0.088 mmol) was dissolved in 5 ml of *N,N*-dimethylformamide, then sodium hydride (20 mg, 0.44 mmol) was added. The mixture was stirred for 20 minutes, then 1-bromo-2-fluoroethane (23 mg, 0.176 mmol) was added. After stirring for 16 hours, the reaction was quenched by adding 5 ml of water and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×3), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **21a** (30 mg, yield 61.1%) as a yellow oil.

20

MS *m/z* (ESI): 553.4 [*M*+1].

Step 2

(1*S*,4*S*)-4-(2-fluoroethoxy)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **21**

25

Compound **21a** (30 mg, 0.543 mmol) was dissolved in 10 mL of dichloromethane, then 0.3 mL of a solution of 4*M* hydrochloric acid in 1,4-dioxane was added. The mixture was stirred for 1 hour, then 10 mg of sodium carbonate was added. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **21** (10 mg, yield 40.7%) as a white viscous material.

30


MS m/z (ESI): 453.4 [M+1]

^1H NMR (400 MHz, CDCl_3) δ 9.76 (d, 1H), 9.61 (d, 1H), 8.89 (d, 1H), 8.34 (d, 1H), 7.94 (d, 1H), 7.69 (d, 1H), 7.58 (d, 1H), 7.44 (t, 1H), 4.43-4.49 (m, 2H), 4.28-4.33 (m, 2H), 3.81-3.87 (m, 1H), 3.61-3.71 (m, 2H), 3.51-3.56 (m, 2H), 2.81-2.89 (d, 2H), 2.67 (s, 2H), 2.39-2.43 (m, 4H), 2.30-2.36 (m, 4H), 1.85 (s, 2H), 1.48-1.61 (m, 6H).

Examples 22, 23

(1*S*,4*S*)-4-(methoxymethyl)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **22**

(1*S*,4*R*)-4-(methoxymethyl)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **23**



Step 1

(*S*)-*tert*-butyl (4-methylene-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **22a**

Methyltriphenylphosphonium bromide (2.95 g, 11.5 mmol) was dissolved in 20 mL of tetrahydrofuran. The reaction was cooled to 0°C, added with potassium *tert*-butoxide (1.29 g, 11.5 mmol) and stirred for 30 minutes. Then, **11b** (1g, 7.66 mmol) was added, the reaction was warmed up to room temperature and stirred for 12 hours. The reaction solution was concentrated under reduced pressure and dissolved in methanol. The resulting residue was purified by thin layer chromatography with elution system B to obtain the title compound **22a** (200 mg, yield 22.2%) as a white solid.

MS m/z (ESI): 204.2 [M-55].

Step 2

tert-butyl ((1*S*)-4-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **22b**

22a (780 mg, 3 mmol) was dissolved in 20 mL of tetrahydrofuran, the reaction was cooled to 0°C, then 6 mL of a solution of 1 M borane in tetrahydrofuran was added. The reaction solution was stirred for 5 hours. 12 mL of 3 M sodium hydroxide solution was added, and the mixture was stirred for 30 minutes. After 12 mL of 30% hydrogen peroxide was added, the reaction solution was warmed up to room temperature and stirred for 12 hours. The reaction solution was concentrated under reduced pressure and extracted with dichloromethane. The organic phases were combined, concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **22b** (740 mg, yield 89.2%) as a white solid.

MS m/z (ESI): 222.1 [M-55].

Step 3

tert-butyl ((1*S*)-4-(methoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **22c**

22b (200 mg, 0.72 mmol) was dissolved in 10 mL of tetrahydrofuran, then sodium hydride (60 mg, 1.4 mmol) was added, and the reaction was stirred for 1 hour. Then, iodomethane (123 mg, 0.86 mmol) was added, and the reaction was stirred for 12 hours. The reaction solution was concentrated under reduced pressure and dissolved in methanol. The resulting residue was purified by thin layer chromatography with elution system B to obtain the title compound **22c** (20 mg, yield 9.5%) as a white solid.

MS m/z (ESI): 236.2 [M-55].

Step 4

(1*S*)-4-(methoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **22d**

The crude compound **22c** (20 mg, 0.07 mmol) was dissolved in 10 mL of dichloromethane, then 10 mL of a solution of 4M hydrochloric acid in 1,4-dioxane was added. After stirring for 2 hours, the reaction solution was concentrated under reduced pressure to obtain the crude title compound **22d** (13 mg) as a yellow oil, which was directly used in next step without further purification.

MS m/z (ESI): 192.2 [M-55].

Step 5

(1*S*,4*S*)-4-(methoxymethyl)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **22**

5a (30 mg, 0.116 mmol) and the crude compound **22d** (22 mg, 0.116 mmol) were dissolved in 20 mL of a mixture of dichloromethane and methanol (V:V=1:1), then sodium cyanoborohydride (15 mg, 0.23 mmol) was added. After stirring for 12 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **22** (10 mg, yield 20%) as a white solid and the title compound **23** (8 mg, yield 16%) as a white solid.

MS m/z (ESI): 435.3 [M+1]

Example 22

¹H NMR (400 MHz, CDCl₃) δ 8.26-8.25 (d, 1H), 7.76-7.72 (t, 1H), 7.42-7.40 (d, 1H),


7.34-7.29 (m, 3H), 7.29-7.27 (m, 1H), 7.18-7.16 (m, 1H), 4.16 (s, 1H), 3.75-3.70 (m, 2H), 3.47-3.45 (m, 2H), 3.41 (s, 3H), 3.35-3.33 (m, 1H), 3.18-3.17 (m, 1H), 2.80-2.70 (m, 1H), 2.4-2.33 (m, 1H), 2.28-1.95 (m, 7H), 1.81-1.62 (m, 5H), 1.59-1.51 (m, 1H), 1.46-1.20 (m, 4H), 1.22-1.1 (m, 1H).

5 **Example 23**

¹H NMR (400 MHz, CDCl₃) δ 8.47-8.46 (d, 1H), 7.72-7.68 (t, 1H), 7.39-7.37 (d, 1H), 7.37-7.33 (m, 1H), 7.24-7.21 (m, 1H), 7.15-7.05 (m, 2H), 6.93-6.91 (d, 1H), 3.94 (s, 1H), 3.68-3.60 (m, 2H), 3.59-3.57 (m, 2H), 3.22 (s, 3H), 3.22-3.19 (m, 1H), 2.71-2.70 (m, 1H), 2.34-2.30 (m, 5H), 2.28-2.25 (m, 1H), 1.84-1.81 (m, 1H), 1.81-1.71 (m, 5H), 1.69-1.51 (m, 2H), 1.45-1.4 (m, 2H), 1.32-1.26 (m, 2H), 1.23-1.15 (m, 1H), 1.1-0.95 (m, 1H).

Example 24

15 (*S*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-3',4'-dihydro-2'*H*-spiro[1,3]dithiolane-2,1'-naphthalen]-4'-amine **24**




11 (35 mg, 0.0865 mmol), ethane-1,2-dithiol **24a** (82 mg, 0.865 mmol) and pyridinium *p*-toluenesulfonate (240 mg, 0.952 mmol) were dissolved in 15 mL of toluene, the reaction was warmed up to 110°C and stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **24** (40 mg, yield 96%) as a light yellow solid.

MS *m/z* (ESI): 481.2 [M+1]

25 ¹H NMR (400 MHz, CD₃OD): δ 8.60 (d, 1H), 7.60 (t, 1H), 7.25-7.31 (m, 2H), 7.15-7.20 (m, 4H), 4.26-4.30 (m, 1H), 3.76 (d, 2H), 2.81-3.01 (m, 4H), 2.41-2.60 (m, 2H), 2.21-2.30 (m, 2H), 1.86-2.13 (m, 4H), 1.70-1.81 (m, 2H), 1.41-1.69 (m, 5H), 1.31-1.39 (m, 2H), 1.10-1.20 (m, 2H), 0.71-0.80 (m, 2H).

30 **Example 25**

(1*S*,4*R*)-4-ethoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **25**



Step 1

tert-butyl ((1*S*,4*R*)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **25a**

(*S*)-2-methyl-CBS-oxazaborolidine (221.8 mg, 0.8 mmol) was dissolved in 140 mL of tetrahydrofuran, then borane methylsulfide (2.4 mL, 48 mmol) was added under an argon atmosphere. The reaction was warmed up to 30°C, then 80 mL of a pre-prepared solution of **11b** (10.5 g, 40 mmol) in tetrahydrofuran was added dropwise over 30 minutes. The reaction mixture was stirred for 1 hour at 30°C. 100 mL of methanol was added at 15°C and stirred for 1 hour to quench the reaction. The reaction solution was concentrated under reduced pressure. 200 mL of ethyl acetate and 5 g of activated carbon were added. The mixture was stirred for 30 minutes under micro-boiling, and filtered. The filter cake was washed with ethyl acetate (100 mL×3). The filtrate was concentrated under reduced pressure to obtain the crude title compound **25a** (10.5 g) as a colorless oil.

MS *m/z* (ESI): 264.4 [*M*+1].

Steps 2 to 4

(1*S*,4*R*)-4-ethoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **25**


In accordance with the synthetic route of Example 19, the starting material **14a** was replaced with **25a**, accordingly, the title compound **25** (7 g) as a light red oil was prepared.

MS *m/z* (ESI): 435.5 [*M*+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 0.62 (dt, 1H), 0.92 - 1.03 (m, 1H), 1.12 (t, 3H), 1.34 (td, 2H), 1.41-1.69 (m, 9H), 1.79 (d, 1H), 1.82-1.92 (m, 2H), 2.02 (td, 1H), 2.26-2.38 (m, 2H), 2.43 (d, 1H), 3.37-3.48 (m, 2H), 3.52-3.66 (m, 3H), 4.25 (t, 1H), 7.11-7.16 (m, 2H), 7.16-7.20 (m, 1H), 7.21-7.28 (m, 2H), 7.45 (d, 1H), 7.71 (td, 1H), 8.52 (dd, 1H).

Example 26

(1*S*,4*S*)-4-(ethoxy-*d*₅)-*N*-(2-((*R*)-9-(pyridine-2-yl)-6-oxaspiro[4.5]dec-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **26**



Step 1

tert-butyl ((1*S*,4*S*)-4-(ethoxy-*d*₅)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **26a**

14a (3.3 g, 12.5 mmol) was dissolved in 50 mL of *N,N*-dimethylformamide, then activated molecular sieves were added. After the reaction solution was cooled to 0°C, sodium hydroxide (0.75 g, 18.75 mmol) was added under an argon atmosphere. The reaction was stirred for 0.5 hours at 0°C. Then, deuterated iodoethane-*d*₅ (0.8 mL, 10 mmol) was added, and the reaction was sealed for 16 hours at 0°C. After the reaction was completed, the reaction solution was poured into a mixture of 50 mL of water, 50 mL of *n*-hexane and 5 mL of ethyl acetate, stirred for 10 minutes and filtered. Insolubles were removed. The filtrate was separated into two phases, and the aqueous phase was extracted with a mixture of *n*-hexane and ethyl acetate (V: V=10: 1) (33 mL×2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL×2), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by a CombiFlash flash preparation instrument with elution system B to obtain the title compound **26a** (1.89 g, yield 64%) as a white solid.

MS *m/z* (ESI): 241.4 [*M*-56+1].

Step 2

(1*S*,4*S*)-4-(ethoxy-*d*₅)-1,2,3,4-tetrahydronaphthalen-1-amine **26b**

8 mL of a solution of 4*M* hydrogen chloride in 1,4-dioxane was added to **26a** (1.89 g, 6.38 mmol). The reaction solution was stirred for 1 hour and concentrated under reduced pressure. 30 mL of ethyl acetate was added, and the mixture was concentrated under reduced pressure. 1 mL of saturated sodium carbonate solution was added to the resulting residue, and the mixture was stirred for 5 minutes. 30 mL of ethyl acetate, 2 g of sodium carbonate solid and 10 g of sodium sulfate were added, the reaction solution was stirred for 30 minutes until the solution was no longer turbid. The mixture was

filtrated, and the filtrate was concentrated under reduced pressure to obtain the crude title compound **26b** (1.21 g, a light brown liquid), which was used directly in the next step without further purification.

MS m/z (ESI): 197.4 [M+1].

Step 3

(1*S*,4*S*)-4-(ethoxy-*d*₅)-*N*-(2-((*R*)-9-(pyridine-2-yl)-6-oxaspiro[4.5]dec-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **26**


1a (1.37 g, 5.31 mmol) and the crude compound **26b** (1.21 g, 6.16 mmol) was dissolved in 50 mL of dichloroethane, a drop of acetic acid was added, and the reaction was stirred for 1 hour. Sodium triacetoxyborohydride (2.81 g, 13.27 mmol) was added, and the reaction was stirred for 16 hours. The reaction solution was added with 10 mL of saturated sodium carbonate solution and stirred for 5 minutes. 10 mL of 15% sodium hydroxide solution, 30 mL of water, 30 mL of dichloromethane were added successively, and the mixture was stirred for 5 minutes. Two phases were separated, and the aqueous phase was extracted with dichloromethane (50 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography with elution system A to obtain the title compound **26** (1.7 g, yield 73%) as a light yellow liquid.

MS m/z (ESI): 440.5 [M+1]

¹H NMR (400 MHz, CDCl₃) δ 0.70 (dt, 1H), 1.09 - 1.16 (m, 1H), 1.45 - 1.55 (m, 4H), 1.62 - 1.84 (m, 6H), 1.86 - 2.04 (m, 4H), 2.23 (td, 1H), 2.34 (dd, 1H), 2.44 (dd, 1H), 2.53 (td, 1H), 3.68 (br. s., 1H), 3.72 - 3.81 (m, 2H), 4.34 (t, 1H), 7.11 (ddd, 1H), 7.17 (t, 2H), 7.18 - 7.23 (m, 1H), 7.31 (t, 2H), 7.62 (td, 1H), 8.55 (dd, 1H).

Example 27

(*S*)-4-ethyl-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2-dihydronaphthalen-1-amine **27**



Step 1

(*S,E*)-*tert*-butyl (4-ethylidene-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **27a**

Ethyltriphenylphosphonium bromide (2.1 g, 5.75 mmol) was dissolved in 20 mL of

tetrahydrofuran. Potassium *tert*-butoxide (643 mg, 5.75 mmol) was added in an ice-water bath, and the reaction was stirred for 30 minutes in an ice-water bath. A pre-prepared solution of **11b** (1 g, 3.83 mmol) in tetrahydrofuran was added dropwise, and the mixture was stirred for 16 hours at 25°C. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system B to obtain the titled compound **27a** (530 mg, yield 51 %) as a light yellow oil.

Step 2

(*S*)-4-ethyl-1,2-dihydronaphthalen-1-amine hydrochloride **27b**

27a (273 mg, 1 mmol) was dissolved in 5 mL of dichloromethane, then 2mL of a solution of 4*M* hydrogen chloride in 1,4-dioxane was added. After stirring for 1 hour, the reaction solution was concentrated under reduced pressure to obtain the crude title compound **27b** (173 mg) as a brown oil, which was used directly in the next step without further purification.

Step 3

(*S*)-4-ethyl-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2-dihydronaphthalen-1-amine **27**


1a (150 mg, 0.58 mmol) and the crude compound **27b** (158 mg, 0.58 mmol) were dissolved in 30 mL of mixture of dichloroethane and methanol (V:V=10:1), then sodium triacetoxyborohydride (369 mg, 1.74 mmol) was added. After stirring for 16 hours, the reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **27** (40 mg, yield 17%) as a light yellow solid.


MS *m/z* (ESI): 417.2 [*M*+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.58 (d, 1H), 7.83-7.78 (m, 1H), 7.53-7.48 (m, 3H), 7.33-7.29 (m, 2H), 7.21 (d, 1H), 5.84 (t, 1H), 4.25 (t, 1H), 3.73-3.72 (m, 3H), 3.41-3.31 (m, 2H), 2.81-2.80 (m, 2H), 2.41-2.25 (m, 3H), 1.96-1.90 (m, 3H), 1.85-1.61 (m, 8H), 1.25 (t, 3H), 1.23-1.21 (m, 1H), 0.68-0.65 (m, 1H).

Example 28

(*S*)-4-methylene-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **28**





In accordance with the synthetic route of Example 17, the starting material **17a** was replaced with **22a**, accordingly, the title compound **28** (20 mg) as a brown solid was prepared.


5 MS m/z (ESI): 403.5 [M+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.50 (d, 1H), 7.72 (t, 1H), 7.68-7.21 (m, 6H), 5.95 (d, 1H), 4.09 (d, 1H), 3.71-3.69 (m, 3H), 3.01-2.80 (m, 2H), 2.67-2.63 (m, 2H), 2.11 (d, 1H), 1.74-1.21 (m, 14H), 0.99-0.98 (m, 1H), 0.45-0.42 (m, 1H).

10

Example 29

2-(((1*S*,4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)acetonitrile **29**



15

Step 1

tert-butyl ((1*S*,4*S*)-4-(cyanomethoxy)-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **29a**

20b (40 mg, 0.08 mmol) was dissolved in 10 mL of tetrahydrofuran, then potassium *tert*-butoxide (45 mg, 0.4 mmol) and bromoacetonitrile (20 mg, 0.16 mmol) were added successively, and the reaction was stirred for 16 hours. 20 ml of water and 20 mL of ethyl acetate were added and stirred. The mixture was left to stand and separate, and extracted with ethyl acetate (30 mL×2). The organic phases were combined and concentrated under reduced pressure to obtain the crude title compound **29a** (50 mg) as an oil, which was directly used in the next step without further purification.

25

Step 2

2-(((1*S*,4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)acetonitrile **29**


The crude compound **29a** (50 mg, 0.1 mmol) was dissolved in 10 mL of dichloromethane, then 0.1 mL of a solution of 4 M hydrogen chloride in dioxane was added. The reaction was stirred for 0.5 hour. Aqueous ammonia was added until the reaction solution was alkaline. The mixture was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **29** (10 mg, yield 8%) as a white wax.

MS m/z (ESI): 446.3 [M+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.54 (d, 1H), 7.75-7.72 (m, 1H), 7.43 (d, 1H), 7.37-7.32 (m, 2H), 7.28-7.15 (m, 3H), 4.67 (d, 1H), 4.40 (d, 2H), 4.31 (d, 1H), 3.97 (d, 1H), 3.63-3.51 (m, 2H), 2.41-2.25 (m, 2H), 2.16-2.06 (m, 2H), 2.04-1.87 (m, 2H), 1.86-1.72 (m, 4H), 1.62-1.21 (m, 8H), 1.04-0.94 (m, 1H), 0.68-0.61 (m, 1H).

Example 30

(1*S*,4*R*)-4-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **30**



Step 1

tert-butyl ((1*S*,4*R*)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **30a**

Compound **13** (46 mg, 0.11 mmol), di-*tert*-butyl dicarbonate (27 mg, 0.121 mmol) and triethylamine (23 mg, 0.22 mmol) were dissolved in 15 mL of dichloromethane, and the reaction was stirred for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **30a** (46 mg, yield 82%) as a white solid.

MS m/z (ESI): 507.3 [M+1].

Step 2

tert-butyl ((1*S*,4*R*)-4-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate **30b**

Compound **30a** (46 mg, 0.091 mmol) was dissolved in 10 mL of tetrahydrofuran, then sodium hydride (8 mg, 0.182 mmol) was added. The reaction was stirred for 30 minutes at room temperature. Iodomethane (16 mg, 0.11 mmol) was added, and the reaction was stirred for 16 hours at room temperature. 50 mL of water and 50 mL of ethyl acetate were added, and two phases were separated. The organic phase was concentrated under reduced pressure to obtain the crude title compound **30b** (47 mg) as a brown solid, which was used directly in the next step without further purification. MS *m/z* (ESI): 521.3 [*M*+1].

Step 4

(1*S*,4*R*)-4-methoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **30**


The crude compound **30b** (47 mg, 0.091 mmol) was dissolved in 10 mL of dichloromethane, then 0.1 mL of a solution of 4 *M* hydrogen chloride in 1,4-dioxane was added, and the reaction was stirred for 1 hour. The reaction solution was concentrated under reduced pressure. Ethanol was added to the residue, and the pH was adjusted to 8 by aqueous ammonia. The mixture was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **30** (36 mg, yield 95%) as a yellow viscous material.

MS *m/z* (ESI): 421.3 [*M*+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.55 (d, 1H), 7.75-7.72 (m, 1H), 7.46 (d, 1H), 7.37-7.32 (m, 2H), 7.28-7.15 (m, 3H), 4.67 (d, 1H), 4.30 (d, 1H), 3.97 (d, 1H), 3.64-3.50 (m, 2H), 3.35 (s, 3H), 2.41-2.26 (m, 2H), 2.16-2.06 (m, 2H), 2.04-1.87 (m, 2H), 1.86-1.72 (m, 4H), 1.62-1.21 (m, 8H), 1.04-0.94 (m, 1H), 0.68-0.61 (m, 1H).

Example 31

2-((*S*,*E*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2*H*)-ylidene)acetonitrile **31**



Step 1

(*S,E*)-*tert*-butyl (4-(cyanomethylene)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate **31a**

Diethyl cyanomethylphosphonate (200 mg, 0.76 mmol) was dissolved in 20 mL of tetrahydrofuran. Sodium hydride (61 mg, 1.52 mmol) was added in an ice-water bath, and the reaction was stirred for 30 minutes in an ice-water bath. A pre-prepared solution of **11b** (200 mg, 0.76 mmol) in tetrahydrofuran was added dropwise, and the mixture was stirred for 16 hours at 25°C. The reaction solution was poured to ice-water and extracted with ethyl acetate three times. The organic phases were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system B to obtain the titled compound **31a** (150 mg, yield 69 %) as a colorless viscous material.

MS m/z (ESI): 285.1 [M+1].

Step 2

(*S,E*)-2-(4-amino-3,4-dihydronaphthalen-1(2*H*)-ylidene)acetonitrile hydrochloride **31b**

31a (150 mg, 0.52 mmol) was dissolved in 5 mL of dichloromethane, then 2mL of a solution of 1*M* hydrochloric acid in 1,4-dioxane was added. The reaction was stirred for 3 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound **31b** (110 mg) as a white solid, which was directly used in the next step without further purification.

Step 3

2-((*S,E*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-3,4-dihydronaphthalen-1(2*H*)-ylidene)acetonitrile **31**


5a (100 mg, 0.39 mmol) and the crude compound **31b** (85 mg, 0.39 mmol) were dissolved in 10 mL of a mixture of dichloroethane and methanol (V:V=10:1), then sodium triacetoxyborohydride (165 mg, 0.78 mmol) was added, and the reaction was stirred for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **31** (30 mg, yield 18%) as a light yellow viscous material.

MS m/z (ESI): 428.0 [M+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.57 (d, 1H), 7.86-7.78 (m, 1H), 7.76-7.74 (m, 1H), 7.39-7.22 (m, 3H), 7.26-7.23 (m, 2H), 6.36-6.35 (m, 1H), 3.65-3.54 (m, 3H), 2.90-2.60 (m, 2H), 2.42-2.37 (m, 3H), 2.03-1.90 (m, 4H), 1.82-1.78 (m, 2H), 1.51-1.24 (m, 10H).

Example 32

2-((4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile **32**



2-((4*S*)-4-amino-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile hydrochloride **32a**

5 **31b** (50 mg, 0.227 mmol) was dissolved in 5 mL of ethanol, then 5 mg of Pd/C was added, and the reaction system was purged with hydrogen three times. The reaction was stirred for 16 hours at room temperature under a hydrogen atmosphere. Insolubles were removed by filtration, and the filtrate was concentrated under reduced pressure to obtain the crude title compound **32a** (45 mg) as a colorless viscous material, which was used directly in the next step without further purification.

Step 2

2-((4*S*)-4-((2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile **32**


15 **5a** (53 mg, 0.2 mmol) and the crude compound **32b** (25 mg, 0.2 mmol) were dissolved in 10 mL of a mixture of dichloroethane and methanol (V:V=10:1), then sodium triacetoxyborohydride (80 mg, 0.4 mmol) was added, and the reaction was stirred for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer chromatography with elution system A to obtain the title compound **32** (5 mg, yield 5.8%) as a light yellow viscous material.


20 MS *m/z* (ESI): 430.3 [M+1]

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.55 (d, 1H), 7.85-7.78 (m, 1H), 7.75-7.72 (m, 1H), 7.35-7.20 (m, 3H), 7.25-7.21 (m, 2H), 3.75-3.60 (m, 3H), 2.95-2.80 (m, 2H), 2.70-2.65 (m, 4H), 2.41-2.30 (m, 4H), 1.95-1.89 (m, 4H), 1.85-1.60 (m, 4H), 1.55-1.21 (m, 6H).

25 Example 33

(*S*)-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-3,4-dihydro-2*H*-spiro[[1,3]dioxolane-2,1'-naphthalen]-4'-amine **33**





In accordance with the synthetic route of Example 27, the starting material **2** was replaced with **11**, accordingly, the title compound **33** (5 mg) as a yellow oil was prepared.


5 MS m/z (ESI): 449.0[M+1]

¹H NMR (400 MHz, DMSO-*d*₆) : δ 8.58 (d, 1H), 7.81 (s, 1H), 7.77-7.70 (m, 1H), 7.51 (d, 1H), 7.27-7.11 (m, 4H), 3.85 (s, 1H), 3.66-3.50 (m, 5H), 3.51-3.42 (m, 1H), 3.42-3.33 (m, 1H), 2.48-2.35 (m, 2H), 2.38-2.32 (m, 1H), 2.20-2.08 (m, 2H), 2.01-1.88 (m, 2H), 1.85-1.75 (m, 3H), 1.71-1.31 (m, 8H), 1.00-0.96 (m, 1H), 0.70-0.62 (m, 1H).

10

Example 34

(1*S*,4*S*)-4-propoxy-*N*-(2-((*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine **34**



15

In accordance with the synthetic route of Example 21, the starting material 1-bromo-2-fluoroethane was replaced with iodopropane, accordingly, the title compound **34** (8 mg) as a yellow solid was prepared.

MS m/z (ESI): 449.3 [M+1]

20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.53 (d, 1H), 7.75-7.70 (m, 1H), 7.45 (d, 1H), 7.37-7.33 (m, 2H), 7.28-7.17 (m, 3H), 4.65 (d, 1H), 4.32 (d, 1H), 3.98 (d, 1H), 3.64-3.52 (m, 3H), 3.49-3.40 (m, 1H), 2.62-2.52 (m, 1H), 2.41-2.27 (m, 2H), 2.16-2.06 (m, 1H), 2.04-1.87 (m, 2H), 1.86-1.71 (m, 5H), 1.67 (d, 1H), 1.60-1.20 (m, 8H), 1.13 (t, 3H), 1.03-0.95 (m, 1H), 0.68-0.60 (m, 1H).

25

BIOLOGICAL ASSAY

The present invention will be further described with reference to the following test examples, but the examples should not be considered as limiting the scope of the

invention.

Test Example 1

1. Experimental Object

The object of this experiment is to determine the agonistic effect of the compounds of the present invention on MOR, KOR, DOR, and to evaluate the *in vitro* activity of the compounds according to the values of EC₅₀ and Emax.

2. MOR activity test

2.1 Experimental Object

The compounds of the present invention can activate μ -opioid receptors (MOR). Activated MOR can regulate intracellular cAMP level, and cAMP enters the nucleus and binds to the CRE region of the reporter gene luciferase, thereby initiating the expression of the reporter gene. Luciferase can react with its substrate to emit fluorescence, and the measured fluorescence signals reflect the agonistic activity of the compounds.

2.2 Experimental Method

The activity of the test example compounds on agonizing MOR and affecting downstream cAMP level was tested by the following method.

2.1.1 Experimental Materials

Reagent name	Supply company	Item number
HEK293 cell line	Cell bank of the typical culture preservation Committee of Chinese Academy of Sciences	<u>GNHu43</u>
DMSO	Shanghai titanchem	G75927B
DMEM high glucose medium	Thermo HyCLone	SH30243018
Fetal bovine serum (FBS)	Gibco	10099-141
CRE/pGL4.29	Promega	E8471
MOR-1/pcDNA3.1(+)	GENEWIZ Biological Technology Co., Ltd	Synthesis
ONE-Glo Luciferase Assay System	Promega	E6110

2.2.2 Experimental Procedure

1) Obtaining HEK293/MOR/CRE monoclonal cell lines

MOR/pcDNA3.1 (+) and CRE/pGL4.29 were transferred into HEK293 cells. G418 and hygromycin were added into the culture medium, and HEK293/MOR/CRE monoclonal cell lines were screened in a 96-well cell culture plate.

2) Agonistic effect of example compounds on MOR

HEK293/MOR/CRE monoclonal cells were cultured in a DMEM/high glucose

medium (10% FBS, 1 mg/ml G418, 200 µg/ml hygromycin, mixed uniformly), and passaged every 3 days. On the day of experiment, a cell suspension was prepared with a fresh cell medium, added to a 96 well plate (BD, #356692) with 20,000 cells/well, and incubated in 5% CO₂ at 37°C. On second day, the compound was dissolved in pure DMSO at a concentration of 20 mM, then formulated with DMSO to a first concentration of 4 mM and diluted in 10 fold concentration gradient to 6 concentrations. 90 µl of DMSO was added to blank and control wells; then 2.5 µl of the compound solutions formulated in DMSO at a gradient concentration to 97.5 µl of a fresh cell culture medium containing 5 µM foscolin; 10 µl of the formulated compound was added to the cell culture plate to make the final concentration of the compound to be 10000, 1000, 100, 10, 1, 0.1, 0.01 nM, and the plate was incubated at 37°C, in 5% CO₂ for 5 hours. In a 96-well cell culture plate, 100 µl of luciferase assay solution (Promega, # E6110) was added to each well. The plate was placed in the dark at room temperature for 10-15 minutes, blowed and aspirated 10 times, and 100 µl were pipetted to a 96 well white plate. The chemiluminescence signal values were readed in a microplate reader (PE, Victor3), and the read data was processed using software.

2.3 Test results

The activity of the compound of the present invention on agonizing MOR and affecting downstream cAMP level was determined by the above test, and the EC₅₀ value is shown in table 1.1. Emax is the maximum effect of the example compound on activating MOR and affecting the cAMP signaling pathway (the maximum effect of TRV-130 is 100%).

3. KOR and DOR activity test

3.1 Experimental Object

The experiment object is to determine the activity of the compounds of the present invention on agonizing KOR receptor and DOR receptor and affecting downstream cAMP levels

3.2 Experimental Procedure

90 µl of HEK293/KOR/CRE or HEK293/DOR/CRE (CRE cDNA purchased from Promega, product number E8471, KOR cDNA and DOR cDNA were constructed by our company) cells were inoculated in a 96-well plate with a density of 1×10^4 cells/well, then the cells were incubated overnight at 37°C, in 5% CO₂. The drug was prepared as a 20 mM stock solution that was later diluted with a 100% DMSO to a 200×concentration gradient, and then diluted with a 20-fold DMEM/high glucose (SH30243.01B, Hyclone) medium. The cell culture plate inoculated on the first day was taken out, and 10 µl of the diluted drug or control (0.5% DMSO) was added to each well. The plate was gently shaken and placed in a incubator at 37°C, 5% CO₂ for 4 hours. Finally, 100 µl of a detection reagent ONE-Glo (E6120, Promega) was added to each well, and the plate was placed at room temperature for 5 minutes. The absorbance value was measured by the cold light model of a microplate reader (PE, Victor3). The EC₅₀ value of the compound was calculated by Graphpad Prism software according to each concentration

of the compound and the corresponding signal value. Emax is the maximum effect of the compound on cAMP level change.

3.3 Test Results

The activity of the compound of the present invention on agonizing KOR receptor or DOR receptor and affecting downstream cAMP level was determined by the above test, and the EC₅₀ value is shown in table 1.2. Emax is the maximum effect of the example compound on affecting cAMP level (The maximum effect of morphine is 100%).

Table1.1: EC₅₀ and Emax values of the compound of present the invention on agonizing MOR receptor and affecting cAMP level

Example No.	MOR	
	EC ₅₀ (nM)	Emax
1	10	102%
2	>10000	0
3	2	124%
4	1	129%
5	5	122%
6	1	115%
7	>10000	0
8	3	114%
9	>10000	48%
10	4	113%
11	17	112%
12	2	125%
13	8	130%
14	3	109%
15	>10000	0
16	9	122%
17	>10000	0
18	>10000	4%
19	2	98%
21	5	110%
22	4	103%
23	5	120%
24	0.8	102%
29	7	112%

30	2	126%
32	0.8	133%

Table1.2: EC₅₀ and Emax values of the compound of present the invention on agonizing KOR receptor and DOR receptor and affecting downstream cAMP level

Example No.	KOR		DOR	
	EC ₅₀ (nM)	Emax	EC ₅₀ (nM)	Emax
11	277	98%	1916	80%
14	1469	74%	1507	91%
19	862	96%	552	108%
20	710	103%	1525	118%
21	1184	100%	1487	107%
22	3091	97%	2404	102%

5 Conclusion: The agonist activity of the compounds of the present invention on KOR receptor or DOR receptor is weak obviously; and the compounds of the present invention have high selectivity to MOR receptor.

Test Example 2

10 1. Experimental Object

The experiment object is to determine the activity of the compound of the present invention on activating the β -arrestin signaling pathway of MOR receptor.

2. Experimental Method

2.1 Experiment Procedure

15 90 μ l of CHO-K1 OPRM1 β -Arrestin(93-0213C2, DiscoverRX) cells were inoculated in a 96-well plate with a density of 1×10^4 cells/well, then the cells were incubated overnight at 37°C, in 5% CO₂. The drug was prepared as a 20 mM stock solution that was later diluted with a 100% DMSO to a 200 $\times$ concentration gradient, and then diluted with a 20-fold AssayComplete™ Cell Plating 2 Reagent (93-0563R2B, DiscoverRX) medium. The cell culture plate inoculated on the first day was taken out, and 10 μ l of the diluted drug or control (0.5% DMSO) was added to each well. The plate was gently shaken and placed in a incubator at 37°C, 5% CO₂ for 90 minutes. Finally, 50 μ l of a detection reagent (93-0001, DiscoverRX) was added to each well, and the plate was placed at room temperature for 60 minutes. The absorbance value was measured by the cold light model of a microplate reader (PE, Victor3). The EC₅₀ value of the compound was calculated by Graphpad Prism software according to each concentration of the compound and the corresponding signal value.

2.2 Test Results

The activity of the compound of the present invention on activating the β -arrestin

signaling pathway was determined by the above assay, and the EC₅₀ value is shown in table 2. Emax is the maximum effect of the compound on affecting the β -arrestin signaling pathway (The maximum effect of morphine is 100%).

Table 2: EC₅₀ value of the compound of present the invention on the β -arrestin signaling pathway

Example No.	EC ₅₀ (nM)	Emax
1	4	12%
2	>10000	4%
11	305	37%
14	26	24%
16	94	9%
19	24	13%
20	4	9%
22	41	18%
24	6	30%
28	15	22%
29	33	32%
33	73	27%
34	16	10%

Conclusion: The compounds of the present invention have little activation effect on the β -arrestin signaling pathway

Test Example 3

1. Experimental Object

The blocking effect of the compound of the present invention and the positive compound TRV-130 (Journal of Pharmacology and Experimental Therapeutics, Volume 344, Issue 3, Pages 708-717, 2013) on hERG potassium current was tested on a stable cell line transfected with hERG potassium channel using an automatic patch clamp.

2. Experimental Method

2.1 Experimental Materials and Instruments

2.1.1 Experimental Materials:

Reagent name	Supply company	Item number
FBS	GIBCO	10099
Sodium pyruvate solution	sigma	S8636-100ML
MEM Non-essential amino acid solution (100×)	sigma	M7145-100ML
G418 sulfate	Enzo	ALX-380-013-G005

hERG cDNA	Origene	-
-----------	---------	---

2.1.2 Instruments

Instrument name	Supply company	Modle
Patchliner 4 channel	nanion	2-03-03100-002
Patchliner cleaning station	nanion	2-02-03201-005
Patchliner cell bank	nanion	2-02-03105-000
Elektrodenchloridierer Patchliner	nanion	3-02-03533-000
HEAK EPC10 Patch clamp amplifier	nanion	1-01-10012-000
Osmotic pressure molar concentration analyzer	Gonoter	Gonoter 030
pH meter	Mettler Toledo	FE20

2.2 Experimental procedure of automatic patch clamp

5 HEK293-hERG stabilized cells were subcultured at a density of 1: 4 in a MEM/EBSS medium (10% FBS, 400 μ g/ml G418, 1% MEM nonessential amino acid solution (100 $\times$), 1% sodium pyruvate solution) for 48-72 hours, then the automatic patch clamp experiment was performed. The cells were digested with 0.25% trypsin on the day of experiment, then the cells were collected by centrifugation and resuspended with extracellular fluid (140 mM NaCl, 4 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 5 mM D-glucose monohydrate, 10 mM Hepes, pH 7.4, 298 mOsmol) into a cell suspension. The cell suspension was placed on the cell bank of the Patchliner instrument, and the cells were added to the chip (NPC-16) by the negative pressure controller of the Patchliner instrument, and the negative pressure attracted individual cells to the small hole of the chip. After the whole cell model is formed, the instrument will generate the hERG current according to the preset hERG current and voltage program, and then the instrument can perfuse the compound from low concentration to high concentration automatically. HEAK Patchmaster, HEAK EPC10 patch clamp amplifier (Nanion), Pathlinersoftware, and a data analysis software provided by Pathcontrol HTsoftware were used to analyze the current of the compounds at different concentration and the current of the blank control.

2.3 Test results

The blocking effect of the compound of the present invention on hERG potassium current was determined by the above test, and the IC₅₀ values are shown in Table 3.

25 Table 3: IC₅₀ of the compound of the present invention on blocking hERG potassium current


Example No.	IC ₅₀ (μ M)
-------------	-----------------------------

TRV-130	1.6
1	13
3	>30
5	6.2
6	3.8
11	4.1
12	10.2
13	13.5
14	8.6
16	10
19	5.9
21	4.2
22	3.8
24	2.5

Conclusion: The compounds of the present invention have a weaker inhibitory effect on hERG than the positive control, and there is a significant difference.

What is claimed is:

1. A compound of formula (I):



or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from the group consisting of cycloalkyl and heterocyclyl;

R is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^3$, $-C(O)R^3$, $-C(O)OR^3$, $-S(O)_mR^3$ and $-NR^4R^5$;

each R^1 is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^3$, $-C(O)R^3$, $-C(O)OR^3$, $-S(O)_mR^3$ and $-NR^4R^5$, wherein the alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

each R^2 is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, oxo, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^3$, $-C(O)R^3$, $-C(O)OR^3$, $-S(O)_mR^3$ and $-NR^4R^5$, wherein the alkyl, alkoxy, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

or two R^2 are taken together to form a cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R^3 is selected from the group consisting of hydrogen, alkyl, deuterated alkyl, amino, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by

one or more groups selected from the group consisting of alkyl, halogen, hydroxy, amino, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R^4 and R^5 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxyalkyl, hydroxy, amino, alkoxycarbonyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, halogen, hydroxy, amino, alkoxycarbonyl, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;


p and q are each independently 0, 1, 2, 3 or 4; and

m is 0, 1 or 2.

2. The compound of formula (I) according to claim 1, wherein ring A is selected from the group consisting of 5 to 6 membered heterocyclyl and 5 to 6 membered cycloalkyl.

3. The compound of formula (I) according to claim 1 or 2, wherein R is pyridyl.

4. The compound of formula (I) according to claim 1, being a compound of formula (II):



or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:

G is selected from the group consisting of a bond, CR^aR^b , $C=O$, NR^4 and oxygen;

R^a and R^b are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxy, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^3$, $-C(O)R^3$, $-C(O)OR^3$, $-S(O)_mR^3$ and $-NR^4R^5$, wherein the alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;


or R^a and R^b are taken together to form a cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted by one or more groups selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy,

alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and R^1 to R^5 , p, m and q are as defined in claim 1.

5. The compound of formula (I) according to any one of claims 1 to 4, wherein R^1 is hydrogen or halogen.

6. The compound of formula (I) according to any one of claims 1 to 5, wherein R^2 is selected from the group consisting of hydrogen, alkyl, oxo, alkoxy, hydroxy, halogen and $-OR^3$, wherein the alkyl and alkoxy are each optionally substituted by one or more groups selected from the group consisting of deuterium, alkyl, halogen, hydroxy, amino, alkoxycarbonyl, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R^3 is selected from the group consisting of hydrogen, alkyl and cycloalkyl, wherein the alkyl is optionally substituted by halogen or cycloalkyl; preferably, R^2 is alkyl, wherein the alkyl is optionally substituted by alkoxy, cycloalkyl or haloalkyl; preferably, R^3 is hydrogen, alkyl, haloalkyl or cycloalkyl.


7. The compound of formula (I) according to claim 1, being a compound of formula (IV):




(IV)


or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 and p are as defined in claim 1.

8. The compound of formula (I) according to any one of claims 1 to 7, wherein the compound is selected from the group consisting of:





9. A process for preparing the compound of formula (I) according to claim 1, comprising a step of:



reacting a compound of formula (VB) with a compound of formula (VIB) or hydrochloride thereof via a reductive amination to obtain the compound of formula (I);

wherein:

ring A, R, R¹, R², p and q are as defined in claim 1.

10. A pharmaceutical composition comprising a therapeutically effective amount of

the compound of formula (I) according to any one of claims 1 to 8, and one or more pharmaceutically acceptable carriers, diluents or excipients.

11. Use of the compound of formula (I) according to any one of claims 1 to 8, or the pharmaceutical composition according to claim 10 for preventing and/or treating a MOR agonist receptor mediated and related disease.

12. The use according to claim 11, wherein the MOR agonist receptor mediated and related disease is selected from the group consisting of pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urinary and reproductive diseases, cardiovascular diseases and respiratory diseases, preferably pain.

13. Use of the compound of formula (I) according to any one of claims 1 to 8, or the pharmaceutical composition according to claim 10 for preventing or treating pain and pain related diseases.

14. The use according to claim 13, wherein the pain is selected from the group consisting of postoperative pain, cancer-induced pain, neuropathic pain, traumatic pain and inflammatory pain.

15. The use according to claim 14, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, cervical cancer, skin cancer, prostate cancer, ovarian cancer, fallopian tube tumor, ovarian tumor, hemophilia and leukemia.

16. Use of the compound of formula (I) according to any one of claims 1 to 8, or the pharmaceutical composition according to claim 10 for agonizing or antagonizing MOR receptor.

17. The use according to any one of claims 11 to 16, wherein the compound of formula (I) or the pharmaceutical composition is used in the preparation of a medicament for preventing and/or treating a MOR agonist receptor mediated and related disease.

18. A method of preventing and/or treating a MOR agonist receptor mediated and related disease in a subject by administering to the subject the compound of formula (I) according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 10.

19. The method according to claim 18, wherein the MOR agonist receptor mediated and related disease is selected from the group consisting of pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urinary and reproductive diseases, cardiovascular diseases and respiratory diseases,

preferably pain.

20. A method of preventing and/or treating pain and pain related diseases in a subject by administering to the subject the compound of formula (I) according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 10.

21. The method according to claim 20, wherein the pain is selected from the group consisting of postoperative pain, cancer-induced pain, neuropathic pain, traumatic pain and inflammatory pain.

22. The method according to claim 21, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, cervical cancer, skin cancer, prostate cancer, ovarian cancer, fallopian tube tumor, ovarian tumor, hemophilia and leukemia.